1
|
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. Lancet Oncol 2024; 25:117-125. [PMID: 38092009 DOI: 10.1016/s1470-2045(23)00589-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 11/08/2023] [Accepted: 11/10/2023] [Indexed: 01/07/2024]
Abstract
BACKGROUND Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, has shown encouraging anti-tumour activity in heavily pre-treated patients with relapsed or refractory peripheral T-cell lymphoma in a phase 1 study (JACKPOT8 Part A). Here, we report the full analysis of a phase 2 study, in which we assessed the anti-tumour activity of golidocitinib in a large multinational cohort of patients. METHODS We did a single-arm, multinational, phase 2 trial (JACKPOT8 Part B) in 49 centres in Australia, China, South Korea, and the USA. Eligible patients were adults (aged ≥18 years) with relapsed or refractory peripheral T-cell lymphoma who had received at least one previous line of systemic therapy and an Eastern Cooperative Oncology Group performance status of 0-2. Patients were given oral golidocitinib 150 mg once daily until disease progression or other discontinuation criteria were met. The primary endpoint was the CT-based objective response rate, assessed by an independent review committee (IRC) per Lugano 2014 classification. The activity analysis set included all patients who received at least one dose and whose pathological diagnosis of peripheral T-cell lymphoma had been retrospectively confirmed by a central laboratory and who had at least one measurable lesion at baseline assessed by IRC. The safety analysis set included all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04105010, and is closed to accrual and follow-up is ongoing. FINDINGS Between Feb 26, 2021, and Oct 12, 2022, we assessed 161 patients for eligibility, of whom 104 (65%) were enrolled and received at least one dose of study drug; the activity analysis set included 88 (85%) patients (median age 58 years [IQR 51-67], 57 [65%] of 88 were male, 31 [35%] were female, and 83 [94%] were Asian). As of data cutoff (Aug 31, 2023; median follow-up was 13·3 months [IQR 4·9-18·4]), per IRC assessment, the objective response rate was 44·3% (95% CI 33·7-55·3; 39 of 88 patients, p<0·0001), with 21 (24%) patients having a complete response and 18 (20%) having a partial response. In the safety analysis set, 61 (59%) of 104 patients had grade 3-4 drug-related treatment-emergent adverse events. The most common grade 3-4 drug-related treatment-emergent adverse events were neutrophil count decreased (30 [29%]), white blood cell count decreased (27 [26%]), lymphocyte count decreased (22 [21%]), and platelet count decreased (21 [20%]), which were clinically manageable and reversible. 25 (24%) patients had treatment-related serious adverse events. Deaths due to treatment-emergent adverse events occurred in three (3%) patients: two (2%) due to pneumonia (one case with fungal infection [related to golidocitinib] and another one with COVID-19 infection) and one (1%) due to confusional state. INTERPRETATION In this phase 2 study, golidocitinib showed a favourable benefit-risk profile in treating relapsed or refractory peripheral T-cell lymphoma. The results of this study warrant further randomised clinical studies to confirm activity and assess efficacy in this population. FUNDING Dizal Pharmaceutical.
Collapse
Affiliation(s)
- Yuqin Song
- Peking University Cancer Hospital, Beijing, China
| | - Luis Malpica
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Qingqing Cai
- Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Weili Zhao
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | | | - Jianqiu Wu
- Jiangsu Cancer Hospital-Jiangsu Institute of Cancer Research, Nanjing, China
| | - Huilai Zhang
- Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | | | | | - Yao Liu
- Chongqing Cancer Hospital, Chongqing, China
| | - Zengjun Li
- Shandong First Medical University Affiliated Cancer Hospital, Jinan, China
| | - Liling Zhang
- Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
| | | | - Jie Jin
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Haiyan Yang
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China
| | | | | | - Sujun Gao
- The First Hospital of Jilin University, Changchun, China
| | - Wenyu Li
- Guangdong Provincial People's Hospital, Guangzhou, China
| | - Zhimin Zhai
- Hematologic Department, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Liqun Zou
- West China Hospital, Sichuan University, Chengdu, China
| | - Yaming Xi
- The First Hospital of Lanzhou University, Lanzhou, China
| | - Youngil Koh
- Seoul National University Hospital, Seoul, South Korea
| | - Fei Li
- The First Affiliated Hospital of Nanchang University, Nanchang, China
| | | | - Hui Zhou
- Hunan Cancer Hospital, Changsha, China
| | - Lie Lin
- Hainan General Hospital, Haikou, China
| | - Hui Liu
- Beijing Hospital, Beijing, China
| | - Pamela Allen
- Winship Cancer Institute of Emory University, Atlanta, GA, USA
| | | | | | | | - Jun Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.
| |
Collapse
|
2
|
An P, Awe C, Barbeau PS, Becker B, Belov V, Bernardi I, Bock C, Bolozdynya A, Bouabid R, Brown A, Browning J, Cabrera-Palmer B, Cervantes M, Conley E, Daughhetee J, Detwiler J, Ding K, Durand MR, Efremenko Y, Elliott SR, Fabris L, Febbraro M, Gallo Rosso A, Galindo-Uribarri A, Germer AC, Green MP, Hakenmüller J, Heath MR, Hedges S, Hughes M, Johnson BA, Johnson T, Khromov A, Konovalov A, Kozlova E, Kumpan A, Kyzylova O, Li L, Link JM, Liu J, Mahoney M, Major A, Mann K, Markoff DM, Mastroberti J, Mattingly J, Mueller PE, Newby J, Parno DS, Penttila SI, Pershey D, Prior CG, Rapp R, Ray H, Raybern J, Razuvaeva O, Reyna D, Rich GC, Ross J, Rudik D, Runge J, Salvat DJ, Sander J, Scholberg K, Shakirov A, Simakov G, Sinev G, Skuse C, Snow WM, Sosnovtsev V, Subedi T, Suh B, Tayloe R, Tellez-Giron-Flores K, Tsai YT, Ujah E, Vanderwerp J, van Nieuwenhuizen EE, Varner RL, Virtue CJ, Visser G, Walkup K, Ward EM, Wongjirad T, Yoo J, Yu CH, Zawada A, Zettlemoyer J, Zderic A. Measurement of Electron-Neutrino Charged-Current Cross Sections on ^{127}I with the COHERENT NaIνE Detector. Phys Rev Lett 2023; 131:221801. [PMID: 38101357 DOI: 10.1103/physrevlett.131.221801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 10/02/2023] [Accepted: 11/08/2023] [Indexed: 12/17/2023]
Abstract
Using an 185-kg NaI[Tl] array, COHERENT has measured the inclusive electron-neutrino charged-current cross section on ^{127}I with pion decay-at-rest neutrinos produced by the Spallation Neutron Source at Oak Ridge National Laboratory. Iodine is one the heaviest targets for which low-energy (≤50 MeV) inelastic neutrino-nucleus processes have been measured, and this is the first measurement of its inclusive cross section. After a five-year detector exposure, COHERENT reports a flux-averaged cross section for electron neutrinos of 9.2_{-1.8}^{+2.1}×10^{-40} cm^{2}. This corresponds to a value that is ∼41% lower than predicted using the MARLEY event generator with a measured Gamow-Teller strength distribution. In addition, the observed visible spectrum from charged-current scattering on ^{127}I has been measured between 10 and 55 MeV, and the exclusive zero-neutron and one-or-more-neutron emission cross sections are measured to be 5.2_{-3.1}^{+3.4}×10^{-40} and 2.2_{-0.5}^{+0.4}×10^{-40} cm^{2}, respectively.
Collapse
Affiliation(s)
- P An
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - C Awe
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - P S Barbeau
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - B Becker
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - V Belov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- National Research Center "Kurchatov Institute," Moscow, 123182, Russian Federation
| | - I Bernardi
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - C Bock
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - A Bolozdynya
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - R Bouabid
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - A Brown
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Mathematics and Physics, North Carolina Central University, Durham, North Carolina 27707, USA
| | - J Browning
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | | | - M Cervantes
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - E Conley
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - J Daughhetee
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Detwiler
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - K Ding
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - M R Durand
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - Y Efremenko
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S R Elliott
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - L Fabris
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M Febbraro
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - A Gallo Rosso
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - A Galindo-Uribarri
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - A C Germer
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M P Green
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Hakenmüller
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - M R Heath
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S Hedges
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - M Hughes
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - B A Johnson
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - T Johnson
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - A Khromov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - A Konovalov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - E Kozlova
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - A Kumpan
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - O Kyzylova
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - L Li
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - J Liu
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - M Mahoney
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - A Major
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - K Mann
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | - D M Markoff
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Mathematics and Physics, North Carolina Central University, Durham, North Carolina 27707, USA
| | - J Mastroberti
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - J Mattingly
- Department of Nuclear Engineering, North Carolina State University, Raleigh, North Carolina 27695, USA
| | - P E Mueller
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Newby
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - D S Parno
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S I Penttila
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - D Pershey
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - C G Prior
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - R Rapp
- Washington & Jefferson College, Washington, Pennsylvania 15301, USA
| | - H Ray
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - J Raybern
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - O Razuvaeva
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- National Research Center "Kurchatov Institute," Moscow, 123182, Russian Federation
| | - D Reyna
- Sandia National Laboratories, Livermore, California 94550, USA
| | - G C Rich
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - J Ross
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Mathematics and Physics, North Carolina Central University, Durham, North Carolina 27707, USA
| | - D Rudik
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - J Runge
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - D J Salvat
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - J Sander
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - K Scholberg
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - A Shakirov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - G Simakov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- National Research Center "Kurchatov Institute," Moscow, 123182, Russian Federation
| | - G Sinev
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - C Skuse
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - W M Snow
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - V Sosnovtsev
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - T Subedi
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
- Department of Physical and Environmental Sciences, Concord University, Athens, West Virginia 24712, USA
| | - B Suh
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - R Tayloe
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | | | - Y-T Tsai
- SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - E Ujah
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Mathematics and Physics, North Carolina Central University, Durham, North Carolina 27707, USA
| | - J Vanderwerp
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - E E van Nieuwenhuizen
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - R L Varner
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - C J Virtue
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - G Visser
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - K Walkup
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - E M Ward
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - T Wongjirad
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - J Yoo
- Department of Physics and Astronomy, Seoul National University, Seoul, 08826, Korea
| | - C-H Yu
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - A Zawada
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - J Zettlemoyer
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - A Zderic
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| |
Collapse
|
3
|
Deng L, Li Z, Zhang H, Huang H, Hu J, Liu L, Liu T, Jin J, Zhu Z, Li W, Huang Z, Huang W, Zhou K, Yang H, Zhang M, Ding K, Zhou H, Hu Y, Shuang Y, Cao J, Gao S, Li D, Sun Z, Zhang Q, Yi S, Ji C, Zhang L, Hou C, Du Y, Wang W, Zhao R, Song Y, Zhu J. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. Am J Hematol 2023; 98:1742-1750. [PMID: 37647123 DOI: 10.1002/ajh.27064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 08/06/2023] [Accepted: 08/10/2023] [Indexed: 09/01/2023]
Abstract
Marginal zone lymphoma (MZL) is an indolent type of non-Hodgkin lymphoma that develops through pathological B cell receptor signaling. Orelabrutinib, a new-generation oral small molecule Bruton's tyrosine kinase inhibitor, was evaluated in relapsed/refractory (r/r) MZL patients. Previously treated r/r MZL patients received orelabrutinib 150 mg once daily in a phase 2, multicenter, single-arm study conducted in China. The primary endpoint was overall response rate (ORR) assessed by an Independent Review Committee (IRC) based on the Lugano 2014 classification. Other efficacy, safety, and pharmacokinetic profiles were evaluated as secondary outcome measures. A total of 111 patients were enrolled, of which 90 patients had MZL confirmed by central pathology review, who were mainly with extra-nodal MZL of mucosa-associated lymphoid tissue (MALT, 46.7%) and nodal MZL (35.6%). The majority had late-stage disease, with stage IV accounting for 75.6%. After a median follow-up duration of 24.3 months, the IRC-assessed ORR was 58.9% (95% confidence interval [CI], 48.0-69.2), with rates of complete response and partial response being 11.1% and 47.8%, respectively. The IRC-assessed median duration of response was 34.3 months, and the IRC-assessed median progression-free survival (PFS) was not reached with a 12-month PFS rate of 82.8% (95% CI, 72.6-89.5). The rate of overall survival at 12 months was 91.0% (95% CI, 82.8-95.4). Common all-grade treatment-related adverse events (TRAEs) included anemia (27.9%), neutrophil count decrease (23.4%), white blood cell count decrease (18.0%), platelet count decrease (17.1%), blood present in urine (16.2%), rash (14.4%), and upper respiratory tract infection (10.8%). Thirty-four patients (30.6%) experienced grade 3 or higher TRAEs. Serious TRAEs occurred in 18 patients (16.2%), of which pneumonia (5.4%) was the most common. Seven patients (6.3%) discontinued orelabrutinib due to TRAEs. Orelabrutinib demonstrated high response rates with durable disease remission and was well tolerated in Chinese patients with r/r MZL.
Collapse
Affiliation(s)
- Lijuan Deng
- Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
| | - Zhiming Li
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Huilai Zhang
- Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China
| | - Haiwen Huang
- Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Jianda Hu
- Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Lihong Liu
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Ting Liu
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
| | - Jie Jin
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Zunmin Zhu
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Wenyu Li
- Department of Lymphoma, Guangdong Provincial People's Hospital, Guangzhou, China
| | - Zhenqian Huang
- Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Wenrong Huang
- Department of Hematology, The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, China
| | - Keshu Zhou
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
| | - Haiyan Yang
- Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China
| | - Mingzhi Zhang
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Kaiyang Ding
- Department of Hematological Oncology, Anhui Province Cancer Hospital, Hefei, China
| | - Hui Zhou
- Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, China
| | - Yu Hu
- Department of Hematology, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
| | - Yuerong Shuang
- Department of Hematology and Lymphoma, Jiangxi Cancer Hospital, Nanchang, China
| | - Junning Cao
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - Sujun Gao
- Department of Hematology, The First Hospital of Jilin University, Changchun, China
| | - Dengju Li
- Department of Hematology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
| | - Zimin Sun
- Department of Hematology, Anhui Provincial Hospital, Hefei, China
| | - Qingyuan Zhang
- Department of Internal Medicine-Oncology, Cancer Hospital of Harbin Medical University, Harbin, China
| | - Shuhua Yi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Chunyan Ji
- Department of Oncology Medicine, Qilu Hospital of Shandong University, Jinan, China
| | - Liansheng Zhang
- Department of Oncology Medicine, Lanzhou University Second Hospital, Lanzhou, China
| | - Cheng Hou
- Beijing InnoCare Pharma Tech Co., Ltd., Beijing, China
| | - Yue Du
- Beijing InnoCare Pharma Tech Co., Ltd., Beijing, China
| | - Weige Wang
- Beijing InnoCare Pharma Tech Co., Ltd., Beijing, China
| | - Renbin Zhao
- Beijing InnoCare Pharma Tech Co., Ltd., Beijing, China
| | - Yuqin Song
- Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
| | - Jun Zhu
- Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
| |
Collapse
|
4
|
Zhang LJ, Yang XX, Zhao KZ, Chen SH, Cai MX, Ding K. [Brief introduction on compilation and editions of Yang ke xuan cui]. Zhonghua Yi Shi Za Zhi 2023; 53:240-244. [PMID: 37727003 DOI: 10.3760/cma.j.cn112155-20230113-00005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/21/2023]
Abstract
Yang ke xuan cui («») is a surgical work compiled by Chen Wenzhi () of the Ming Dynasty. There are few of research on the completion and author of the book. Based on the evidences in the local chronicles, the prefaces and postscripts of the book, it has been verified that the book was originally completed no later than 1591, and Chen Wenzhi passed away no later than 1623. After investigating the 6 editions collected by 8 institutions, a collection of 11 books in total, by comparing the characteristics and circulation relationship of each edition, two systems of circulation were sorted out: block-printed edition of Xu Xi () and review edition of Xu Dachun ().
Collapse
Affiliation(s)
- L J Zhang
- Institute of Chinese Medical History and Literature, Chinese Academy of Traditional Chinese Medicine, Beijing 100700, China
| | - X X Yang
- Institute of Chinese Medical History and Literature, Chinese Academy of Traditional Chinese Medicine, Beijing 100700, China
| | - K Z Zhao
- Institute of Chinese Medical History and Literature, Chinese Academy of Traditional Chinese Medicine, Beijing 100700, China
| | - S H Chen
- Institute of Chinese Medical History and Literature, Chinese Academy of Traditional Chinese Medicine, Beijing 100700, China
| | - M X Cai
- Institute of Chinese Medical History and Literature, Chinese Academy of Traditional Chinese Medicine, Beijing 100700, China
| | - K Ding
- Institute of Chinese Medical History and Literature, Chinese Academy of Traditional Chinese Medicine, Beijing 100700, China
| |
Collapse
|
5
|
Xing T, Wang X, Ding K, Ni K, Zhou Q. Improved Artificial Potential Field Algorithm Assisted by Multisource Data for AUV Path Planning. Sensors (Basel) 2023; 23:6680. [PMID: 37571463 PMCID: PMC10422249 DOI: 10.3390/s23156680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 06/21/2023] [Accepted: 06/26/2023] [Indexed: 08/13/2023]
Abstract
With the development of ocean exploration technology, the exploration of the ocean has become a hot research field involving the use of autonomous underwater vehicles (AUVs). In complex underwater environments, the fast, safe, and smooth arrival of target points is key for AUVs to conduct underwater exploration missions. Most path-planning algorithms combine deep reinforcement learning (DRL) and path-planning algorithms to achieve obstacle avoidance and path shortening. In this paper, we propose a method to improve the local minimum in the artificial potential field (APF) to make AUVs out of the local minimum by constructing a traction force. The improved artificial potential field (IAPF) method is combined with DRL for path planning while optimizing the reward function in the DRL algorithm and using the generated path to optimize the future path. By comparing our results with the experimental data of various algorithms, we found that the proposed method has positive effects and advantages in path planning. It is an efficient and safe path-planning method with obvious potential in underwater navigation devices.
Collapse
Affiliation(s)
| | | | | | | | - Qian Zhou
- Division of Advanced Manufacturing, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
| |
Collapse
|
6
|
Xia Y, Wang L, Ding K, Wu J, Yin H, Hu M, Shen H, Liang J, Chen R, Li Y, Zhu H, Li J, Xu W. Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial. Chin Med J (Engl) 2023; 136:1491-1493. [PMID: 37036911 PMCID: PMC10278685 DOI: 10.1097/cm9.0000000000002636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Indexed: 04/12/2023] Open
Affiliation(s)
- Yi Xia
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| | - Li Wang
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| | - Kaiyang Ding
- Department of Hematology, The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui 230001, China
| | - Jiazhu Wu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| | - Hua Yin
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| | - Maogui Hu
- Department of Hematology, The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui 230001, China
| | - Haorui Shen
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| | - Jinhua Liang
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| | - Ruize Chen
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| | - Yue Li
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| | - Huayuan Zhu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| | - Jianyong Li
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
| | - Wei Xu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China
- Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China
| |
Collapse
|
7
|
Huang H, Tao R, Hao S, Yang Y, Cen H, Zhou H, Guo Y, Zou L, Cao J, Huang Y, Jin J, Zhang L, Yang H, Xing X, Zhang H, Liu Y, Ding K, Qi Q, Zhu X, Zhu D, Wang S, Fang T, Dai H, Shi Q, Yang J. Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study. J Clin Oncol 2023; 41:3032-3041. [PMID: 36996373 PMCID: PMC10414714 DOI: 10.1200/jco.22.02367] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 02/20/2023] [Accepted: 02/24/2023] [Indexed: 04/01/2023] Open
Abstract
PURPOSE Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin lymphoma with limited treatment options. This phase II study evaluated the efficacy and safety of sugemalimab, an anti-PD-L1 monoclonal antibody, in R/R ENKTL. METHODS Eligible patients received sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months or until progression, death, or study withdrawal. The primary end point was objective response rate (ORR) assessed by an independent radiologic review committee. Key secondary end points included ORR assessed by the investigators, complete response rate, duration of response, and safety. RESULTS At the data cutoff (February 23, 2022), 80 patients were enrolled and followed for a median of 18.7 months. At baseline, 54 (67.5%) had stage IV disease and 39 (48.8%) had received ≥2 lines of prior systemic therapy. Independent radiologic review committee-assessed ORR was 44.9% (95% CI, 33.6 to 56.6); 28 (35.9%) patients achieved a complete response and seven (9.0%) achieved a partial response, with a 12-month duration of response rate of 82.5% (95% CI, 62.0 to 92.6). Investigator-assessed ORR was 45.6% (95% CI, 34.3 to 57.2), and 24 (30.4%) patients achieved a complete response. Most treatment-emergent adverse events were grade 1-2 in severity, and grade ≥ 3 events were reported in 32 (40.0%) patients. CONCLUSION Sugemalimab showed robust and durable antitumor activity in R/R ENKTL. Treatment was well tolerated with expected safety profile for this drug class.
Collapse
Affiliation(s)
- Huiqiang Huang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Rong Tao
- Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Siguo Hao
- Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yu Yang
- Department of Lymphoma, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China
| | - Hong Cen
- Department of Medical Oncology, Guangxi Cancer Hospital and of Guangxi Medical University Affiliated Cancer Hospital, Nanning, China
| | - Hui Zhou
- Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, China
| | - Ye Guo
- Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
| | - Liqun Zou
- Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China
| | - Junning Cao
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - Yunhong Huang
- Department of Lymphoma, the Affiliated Cancer Hospital of Guiyang Medical University, Guiyang, China
| | - Jie Jin
- Department of Hematology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Liling Zhang
- Department of Lymphoma, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Haiyan Yang
- Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, China
| | - Xiaojing Xing
- Department of Medical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, China
| | - Huilai Zhang
- Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Yanyan Liu
- Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
| | - Kaiyang Ding
- Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China
| | - Qinzhou Qi
- Clinical Department, CStone Pharmaceuticals (Suzhou) Co Ltd, Suzhou, China
| | - Xiaoli Zhu
- Clinical Department, CStone Pharmaceuticals (Suzhou) Co Ltd, Suzhou, China
| | - Dan Zhu
- Clinical Department, CStone Pharmaceuticals (Suzhou) Co Ltd, Suzhou, China
| | - Siyuan Wang
- Clinical Department, CStone Pharmaceuticals (Suzhou) Co Ltd, Suzhou, China
| | - Teng Fang
- Clinical Department, CStone Pharmaceuticals (Suzhou) Co Ltd, Suzhou, China
| | - Hangjun Dai
- Clinical Department, CStone Pharmaceuticals (Suzhou) Co Ltd, Suzhou, China
| | - Qingmei Shi
- Clinical Department, CStone Pharmaceuticals (Suzhou) Co Ltd, Suzhou, China
| | - Jason Yang
- Clinical Department, CStone Pharmaceuticals (Suzhou) Co Ltd, Suzhou, China
| |
Collapse
|
8
|
Xu W, Zhou K, Wang T, Yang S, Liu L, Hu Y, Zhang W, Ding K, Zhou J, Gao S, Xu B, Zhu Z, Liu T, Zhang H, Hu J, Ji C, Wang S, Xia Z, Wang X, Li Y, Song Y, Ma S, Tang X, Zhang B, Li J. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. Am J Hematol 2023; 98:571-579. [PMID: 36683422 DOI: 10.1002/ajh.26826] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 12/05/2022] [Accepted: 12/21/2022] [Indexed: 01/24/2023]
Abstract
Orelabrutinib is a novel, small molecule, selective irreversible Bruton's tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy and safety in patients with refractory or relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This is single-arm, multi-center, open-label, phase 2 study in 80 eligible Chinese patients, who were treated with monotherapy of orelabrutinib at 150 mg once daily. Overall response rate evaluated by an independent review committee was the primary endpoint, and secondary endpoints include progression-free survival, overall survival, and safety. Independent review committee assessed overall response rate was 92.5% (74/80); complete response 21.3% (17/80), partial response 60.0% (48/80), partial response with lymphocytosis 11.3% (9/80). At a 32.3-month median follow-up, the median progression-free survival had not been achieved, while the 30-month progression-free survival rate and overall survival rates were 70.9% (95% confidence interval [CI], 59.5-79.6) and 81.3% (95% CI, 70.8-88.2), respectively. Orelabrutinib also revealed substantial response in patients with high prognostic risks: overall response rates of patients carrying positive TP53 mutational status or del(17p), del(11q), as well as unmutated immunoglobulin heavy-chain variable region gene were 100%, 94.7%, and 93.9%, respectively. Most adverse events were in low grade, with 86.8% of AEs being Grade 1 or 2. Nearly 67% of patients were still receiving orelabrutinib after almost a 3-year follow-up. In conclusion, Orelabrutinib demonstrated compelling efficacy as well as safety profiles, with a noteworthy number of patients obtaining complete response in refractory or relapsed CLL/SLL.
Collapse
Affiliation(s)
- Wei Xu
- Department of Hematology, Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, People's Republic of China
| | - Keshu Zhou
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, People's Republic of China
| | - Tingyu Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China
| | - Shenmiao Yang
- Department of Hematology, Peking University People's Hospital, Beijing, People's Republic of China
| | - Lihong Liu
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China
| | - Yu Hu
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Wei Zhang
- Department of Hematology, Peking Union Medical College Hospital, Beijing, People's Republic of China
| | - Kaiyang Ding
- Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China
| | - Jianfeng Zhou
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Sujun Gao
- Department of Hematology, The First Hospital, Jilin University, Jilin, People's Republic of China
| | - Bing Xu
- Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China
| | - Zunmin Zhu
- Institute of Hematology, Henan Provincial People's Hospital, Zhengzhou, People's Republic of China
| | - Ting Liu
- Department of Hematology, West China Hospital of Sichuan University, Chengdu, People's Republic of China
| | - Huilai Zhang
- Lymphoma, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China
| | - Jianda Hu
- Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China
| | - Chunyan Ji
- Department of Hematology, Qilu Hospital, Shandong University Jinan, Jinan, People's Republic of China
| | - Shunqing Wang
- Department of Hematology, Guangzhou First People's Hospital, Guangzhou, People's Republic of China
| | - Zhongjun Xia
- Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yatsen University Cancer Center, Guangzhou, People's Republic of China
| | - Xin Wang
- Department of Hematology, Shandong Provincial Hospital, Jinan, People's Republic of China
| | - Yan Li
- Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China
| | - Yongping Song
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, People's Republic of China
| | - Shuo Ma
- Department of Clinical Development, InnoCare Pharma Limited, Beijing, People's Republic of China
| | - Xinran Tang
- Department of Clinical Development, InnoCare Pharma Limited, Beijing, People's Republic of China
| | - Bin Zhang
- Department of Clinical Development, InnoCare Pharma Limited, Beijing, People's Republic of China
| | - Jianyong Li
- Department of Hematology, Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, People's Republic of China
| |
Collapse
|
9
|
Wang X, Yu L, Jiang X, Ding K. Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma. Cancer Med 2023; 12:10553-10562. [PMID: 36912128 DOI: 10.1002/cam4.5790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 12/04/2022] [Accepted: 02/27/2023] [Indexed: 03/14/2023] Open
Abstract
BACKGROUND Approximately 40% patients of diffuse large B-cell lymphoma (DLBCL) would develop disease recurrence/progression after first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis. An effective strategy to prolong the survival of this patient population is the additional single-drug maintenance therapy. lenalidomide, an immunomodulatory drug with oral activity, has direct anti-tumor activity and indirect effects mediated by multiple immune cells in the tumor microenvironment, such as B, T, natural killer (NK), and dendritic cells. Combining its controllable toxicity, it is promising in long-term maintenance therapy. This study aims at evaluating the clinical effect of lenalidomide maintenance therapy in responding DLBCL patients with R-CHOP treatment. METHODS This retrospective study was devised in DLBCL cases who obtained complete response (CR) or partial response (PR) following 6-8 cycles of R-CHOP treatment between January 1, 2015 and July 31, 2019. Patients (n = 141) included were respectively assigned to receive lenalidomide maintenance treatment (lenalidomide, n = 50) and drug-free maintenance treatment (control, n = 91) after CR/PR. lenalidomide was provided orally at 25 mg/day for 10 days, with a cycle of 21 days and a treatment course of 2 years. Progression-free survival (PFS) was taken as the primary outcome. RESULTS Of the total 141 subjects, the median follow-up time was 30.9 months (range, 5.7-68.9 months). The 2-year PFS was 84% (95% CI: 74%-94%) in the lenalidomide group and 53% (95% CI: 43%-63%) in the control group. The median PFS of the lenalidomide group was not reached, and that of the control group was 42.9 months (HR = 0.32; 95% CI: 0.16-0.63; p = 0.001). No remarkable difference in overall survival (OS) between the two groups was indicated (HR = 0.42; 95% CI: 0.16-1.12; p = 0.08). Central nervous system (CNS) recurrence happened in 5 patients (5.5%) of the control group, while none of the patients with lenalidomide had CNS recurrence. Additionally, neutropenia and cutaneous reactions were the most common Grade 1-2 adverse reactions after lenalidomide treatment, and neutropenia was the most frequent Grade 3-4 adverse reaction. CONCLUSION Two-year lenalidomide maintenance treatment can significantly prolong the PFS of DLBCL patients who obtained CR/PR to first-line R-CHOP treatment.
Collapse
Affiliation(s)
- Xiaoyan Wang
- Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China
| | - Lu Yu
- Department of Hematology, Anqing Municipal Hospital, Anhui Medical University, Anqing, China
| | - Xinlu Jiang
- Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China
| | - Kaiyang Ding
- Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China.,Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| |
Collapse
|
10
|
Gao Y, Liu Y, Wang Y, Zhang Q, Wu D, Ye X, Wu J, Xu W, Zhou J, Yang Y, Cen H, Zhang F, Xiang Y, Tang X, Ding K, Lin J, Ma L, Wang S, Yu H, Zhao Y, Song B, Lv F, Huang H. Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China. Cancer 2023; 129:551-559. [PMID: 36541221 DOI: 10.1002/cncr.34544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 07/18/2022] [Accepted: 08/03/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND The optimal treatment strategy for refractory or relapse (R/R) indolent non-Hodgkin lymphoma (iNHL) has not been fully identified. This study aims to investigate the efficacy and tolerance of bendamustine hydrochloride developed in native Chinese corporation in the treatment of patients with R/R iNHL. METHODS A total of 101 patients from 19 centers were enrolled in this study from July 2016 to February 2019. Bendamustine hydrochloride (120 mg/m2 ) was given on days 1 and 2 of each 21-day treatment cycle for six planned cycles or up to eight cycles if tolerated. Parameters of efficacy and safety were analyzed. RESULTS The median age of the patients was 53.44 (range, 24.4-74.6) years old. A total of 56 (55.44%) patients completed at least six treatment cycles, and the relative dose intensity was 93.78%. The overall response rate was 72.28%, and the median duration of response was 15.84 months (95% confidence interval [CI], 13.77-27.48 months). Median progression-free survival was 16.52 months (95% CI, 14.72-23.41 months), and the median overall survival was not reached. Grade 3 or 4 hematologic toxicities included neutropenia (77.22%), thrombocytopenia (29.70%), and anemia (15.84%). The most frequent nonhematologic adverse events (any grade) included nausea, vomiting, fatigue, fever, decreased appetite, and weight loss. Seven patients died during the trial, and four cases may be related to the investigational drug. CONCLUSIONS This study reveals that bendamustine hydrochloride is a feasible treatment option for the indolent B-cell non-Hodgkin lymphoma patient who has not remitted or relapsed after treatment with rituximab. All adverse events were predictable and manageable.
Collapse
Affiliation(s)
- Yan Gao
- Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Yizhen Liu
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Yafei Wang
- Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
| | - Qingyuan Zhang
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
| | - Depei Wu
- Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Xu Ye
- Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Jianqiu Wu
- Department of Medical Oncology, Jiangsu Institute of Cancer Research, Jiangsu Red Cross Cancer Center, Jiangsu Cancer Hospital, the Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Wei Xu
- Hematology Department, Jiangsu Province Hospital, Nanjing, China
| | - Jianfeng Zhou
- Hematology Department, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
| | - Yu Yang
- Department of Lymphoma and Head and Neck Cancer, The Affiliated Tumor Hospital of Fujian Medical University, Fuzhou, Fujian Province, China
| | - Hong Cen
- Department of Hematology, Lymphoma and Pediatric Oncology, Guangxi Medical University Affiliated Tumor Hospital and Oncology Medical College, Nanning, China
| | - Feng Zhang
- Department of Hematology, Anhui Oncology Hospital, Bengbu Medical College, Bengbu, China
| | - Ying Xiang
- Department of Hematology and Oncology, Chongqing Cancer Hospital, Chongqing, China
| | - Xiaoqiong Tang
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Kaiyang Ding
- Department of Hematology, Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui Province, China
| | - JinYing Lin
- Department of Hematology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
| | - Lei Ma
- Guangzhou Medical University Affiliated Tumor Hospital and Oncology Medical College, Nanning, China
| | - Shunqing Wang
- Department of Hematology, Guangzhou First People's Hospital, Guangzhou, Guangdong, China
| | - Hao Yu
- Department of Biostatistics, Nanjing Medical University, Nanjing, China
| | - Yang Zhao
- Nanjing Baosida Pharmaceutical Technology Co., Ltd, Nanjing, China
| | - Bin Song
- West China Hospital of Sichuan University, Sichuan, China
| | - Fangfang Lv
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Huiqiang Huang
- Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| |
Collapse
|
11
|
Akimov D, An P, Awe C, Barbeau PS, Becker B, Belov V, Bernardi I, Blackston MA, Bock C, Bolozdynya A, Browning J, Cabrera-Palmer B, Chernyak D, Conley E, Daughhetee J, Detwiler J, Ding K, Durand MR, Efremenko Y, Elliott SR, Fabris L, Febbraro M, Gallo Rosso A, Galindo-Uribarri A, Green MP, Heath MR, Hedges S, Hoang D, Hughes M, Johnson T, Khromov A, Konovalov A, Kozlova E, Kumpan A, Li L, Link JM, Liu J, Mann K, Markoff DM, Mastroberti J, Mueller PE, Newby J, Parno DS, Penttila SI, Pershey D, Rapp R, Raybern J, Razuvaeva O, Reyna D, Rich GC, Ross J, Rudik D, Runge J, Salvat DJ, Salyapongse AM, Sander J, Scholberg K, Shakirov A, Simakov G, Sinev G, Snow WM, Sosnovtsev V, Suh B, Tayloe R, Tellez-Giron-Flores K, Tolstukhin I, Ujah E, Vanderwerp J, Varner RL, Virtue CJ, Visser G, Wongjirad T, Yen YR, Yoo J, Yu CH, Zettlemoyer J. First Probe of Sub-GeV Dark Matter beyond the Cosmological Expectation with the COHERENT CsI Detector at the SNS. Phys Rev Lett 2023; 130:051803. [PMID: 36800477 DOI: 10.1103/physrevlett.130.051803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 11/28/2022] [Indexed: 06/18/2023]
Abstract
The COHERENT Collaboration searched for scalar dark matter particles produced at the Spallation Neutron Source with masses between 1 and 220 MeV/c^{2} using a CsI[Na] scintillation detector sensitive to nuclear recoils above 9 keV_{nr}. No evidence for dark matter is found and we thus place limits on allowed parameter space. With this low-threshold detector, we are sensitive to coherent elastic scattering between dark matter and nuclei. The cross section for this process is orders of magnitude higher than for other processes historically used for accelerator-based direct-detection searches so that our small, 14.6 kg detector significantly improves on past constraints. At peak sensitivity, we reject the flux consistent with the cosmologically observed dark-matter concentration for all coupling constants α_{D}<0.64, assuming a scalar dark-matter particle. We also calculate the sensitivity of future COHERENT detectors to dark-matter signals which will ambitiously test multiple dark-matter spin scenarios.
Collapse
Affiliation(s)
- D Akimov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - P An
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - C Awe
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - P S Barbeau
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - B Becker
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - V Belov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- National Research Center "Kurchatov Institute," Moscow 123182, Russian Federation
| | - I Bernardi
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - M A Blackston
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - C Bock
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - A Bolozdynya
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - J Browning
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | | | - D Chernyak
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - E Conley
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - J Daughhetee
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Detwiler
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - K Ding
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - M R Durand
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - Y Efremenko
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S R Elliott
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - L Fabris
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M Febbraro
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - A Gallo Rosso
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - A Galindo-Uribarri
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M P Green
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | - M R Heath
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S Hedges
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Lawrence Livermore National Laboratory, Livermore, California, 94550, USA
| | - D Hoang
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - M Hughes
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - T Johnson
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - A Khromov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - A Konovalov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- National Research Center "Kurchatov Institute," Moscow 123182, Russian Federation
| | - E Kozlova
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- National Research Center "Kurchatov Institute," Moscow 123182, Russian Federation
| | - A Kumpan
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - L Li
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - J Liu
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - K Mann
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | - D M Markoff
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Mathematics and Physics, North Carolina Central University, Durham, North Carolina 27707, USA
| | - J Mastroberti
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - P E Mueller
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Newby
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - D S Parno
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S I Penttila
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - D Pershey
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - R Rapp
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - J Raybern
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - O Razuvaeva
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- National Research Center "Kurchatov Institute," Moscow 123182, Russian Federation
| | - D Reyna
- Sandia National Laboratories, Livermore, California 94550, USA
| | - G C Rich
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - J Ross
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Mathematics and Physics, North Carolina Central University, Durham, North Carolina 27707, USA
| | - D Rudik
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - J Runge
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - D J Salvat
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - A M Salyapongse
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - J Sander
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - K Scholberg
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - A Shakirov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - G Simakov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- National Research Center "Kurchatov Institute," Moscow 123182, Russian Federation
| | - G Sinev
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - W M Snow
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - V Sosnovtsev
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - B Suh
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - R Tayloe
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | | | - I Tolstukhin
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - E Ujah
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - J Vanderwerp
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - R L Varner
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - C J Virtue
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - G Visser
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - T Wongjirad
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - Y-R Yen
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - J Yoo
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Korea
| | - C-H Yu
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Zettlemoyer
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| |
Collapse
|
12
|
Ding K, Liu H, Ma J, Yang H, Cao L, Wang H, Peng H, Shi W, Zhao X, Wu W, Zhu H, Li J, Fan L. Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica 2023. [PMID: 36700408 PMCID: PMC10388287 DOI: 10.3324/haematol.2022.282266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Indexed: 01/27/2023] Open
Abstract
Although classic Hodgkin lymphoma (cHL) is highly curable with current treatment paradigms, 10-25% of patients experience therapeutic failure. This prospective multicenter phase II study attempted to investigate the efficacy and safety of the combination of tislelizumab with gemcitabine and oxaliplatin (T-GemOx) in relapsed or refractory cHL (R/R cHL). Participants received 6-8 courses of gemcitabine (1 g/m2 on day 1) and oxaliplatin (100 mg/m2 on day 1) combined with tislelizumab (200 mg on day 2) at 21-day intervals, followed by tislelizumab maintenance (every 2 months for 2 years). The main outcome measure was the best complete remission rate (CRR). As of August 2022, a total of 30 patients were consecutively enrolled and provided induction therapy. The best overall response rate and CRR were 100% (95% confidence interval [CI]: 88.4-100%) and 96.7% (95% CI: 82.8-99.9%), respectively. The median duration of follow-up after initiation of T-GemOx was 15.8 months. The 12-month progression-free survival rate without autologous stem cell transplant was 96% (95% CI: 74.8-99.4%). There were 122 adverse events (AEs) recorded, of which 93.4% were grade 1 or 2. Thrombocytopenia (10%) and anemia (6.7%) were the most common grade 3 or 4 AEs. Overall, T-GemOx demonstrated promising antitumor activity with manageable toxicities as a salvage treatment for R/R cHL. A longer follow-up duration is required to determine whether maintenance therapy with tislelizumab rather than transplantation can be curative following such a highly active regimen.
Collapse
Affiliation(s)
- Kaiyang Ding
- Department of Hematology, Anhui Provincial Hospital, the First Affiliated Hospital of USTC, Hefei, Anhui 230002
| | - Hailing Liu
- Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029
| | - Jie Ma
- Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052
| | - Haiyan Yang
- Department of Lymphoma, Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang 310012
| | - Lei Cao
- Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029
| | - Huihan Wang
- Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, Liaoning 110022
| | - Hongling Peng
- Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011
| | - Wei Shi
- Department of Hematology, the Friendship Hospital of Ili Kazakh Autonomous Prefecture, Yining, Xinjiang 835000
| | - Xiaoli Zhao
- Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029
| | - Wei Wu
- Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029
| | - Huayuan Zhu
- Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029
| | - Jianyong Li
- Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029.
| | - Lei Fan
- Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029.
| |
Collapse
|
13
|
Jiang X, Zhang H, Ni J, Zhang X, Ding K. Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development. Front Oncol 2022; 12:1060496. [PMID: 36568181 PMCID: PMC9772875 DOI: 10.3389/fonc.2022.1060496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Accepted: 11/07/2022] [Indexed: 12/14/2022] Open
Abstract
MALT lymphoma is an extranodal B-cell lymphoma of the marginal zone of mucosa-associated lymphoid tissue (MALT), caused by malignant transformation of B-cells in the marginal zone. In this work, we aim to explore the potential relationship between MALT lymphoma and DLBCL. Vaccines derived from messenger ribonucleic acid (mRNA) may provide satisfactory results. Despite being a promising treatment option, immunotherapy isn't widely used in treating renal cell carcinoma, as only a few patients respond to the treatment. The Cancer Genome Atlas (TCGA) analysis revealed gene expression profiles and clinical information. Antigen-presenting cells infiltrated the immune system using TIMER tool (http://timer.cistrome.org/). GDSC (Genomics of Drug Sensitivity in Cancer) data were used to estimate drug sensitivity. Immune-related genes were associated with a better prognosis in MALT lymphoma patients and higher levels of antigen-presenting cells. There is a significant relationship between these immune subtypes and immunological checkpoints, immunogenic cell death regulators, and prognostic variables for MALT lymphoma patients. In this study, we provide a theoretical foundation for the development of mRNA vaccines and suggest that KLHL14 could potentially be used as antigens to develop mRNA vaccines for MALT lymphoma.
Collapse
Affiliation(s)
- Xinlu Jiang
- Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China
| | - Huanhuan Zhang
- Department of Respiratory, Wannan Medical College, Wuhu, Anhui, China
| | - Jinju Ni
- Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China
| | - Xu Zhang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Kaiyang Ding
- Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China,*Correspondence: Kaiyang Ding,
| |
Collapse
|
14
|
Jiang X, Zhang H, Wang X, Zhang X, Ding K. Comprehensive Analysis of the Association between Human Diseases and Water Pollutants. Int J Environ Res Public Health 2022; 19:ijerph192416475. [PMID: 36554354 PMCID: PMC9779172 DOI: 10.3390/ijerph192416475] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 11/28/2022] [Accepted: 12/02/2022] [Indexed: 05/31/2023]
Abstract
Drinking water is an important natural resource. For many people worldwide, especially in developing countries, access to safe drinking water is still a dream. An increasing number of human activities and industrialization have caused various physical, chemical, and biological pollutants to enter water bodies, affecting human health. Water pollutants contain a vast number of additives, such as perfluorinated chemicals, polybrominated diphenyl ethers, phthalate, nanomaterials, insecticides, microcystins, heavy metals, and pharmacologies. In this work, we aim to explore the potential relationship between water pollutants and human diseases. Here, we explored an integrative approach to identify genes, biological processes, molecular functions, and diseases linked to exposure to these water pollutants. These processes and functions affected by water pollutants are related to many diseases, including colonic neoplasms, breast neoplasms, hepatitis B, bladder cancer, and human cytomegalovirus infection. In addition, further analysis revealed the genes that play a key role in the human diseases induced by water pollutants. Therefore, conducting an integrative toxicogenomic analysis of water pollutants is more appropriate for evaluating the potential effects of water pollutants on human health.
Collapse
Affiliation(s)
- Xinlu Jiang
- Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei 230032, China
| | - Huanhuan Zhang
- Department of Respiratory, Wannan Medical College, Wuhu 241002, China
| | - Xiaoyan Wang
- Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei 230032, China
| | - Xu Zhang
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - Kaiyang Ding
- Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei 230032, China
| |
Collapse
|
15
|
Narang A, Shin E, Ding K, Krishnan K, Casey B, Bhutani M, Herman J, Meyer J, Hong T, Koay E. Using Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients with Pancreatic Cancer: A Multi-Institutional Safety and Feasibility Study. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Lin Q, Ding K, Zhao R, Wang H, Ren L, Wei Y, Ye Q, Cui Y, He G, Tang W, Feng Q, Zhu D, Chang W, Lv Y, Mao Y, Wang X, Liang L, Zhou G, Liang F, Xu J. 43O Preoperative chemotherapy prior to primary tumor resection for colorectal cancer patients with asymptomatic resectable primary lesion and synchronous unresectable liver-limited metastases (RECUT): A prospective, randomized, controlled, multicenter clinical trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
17
|
Ding K, Chen F, Priedigkeit N, Brown DD, Weiss K, Watters R, Levine KM, Heim T, Li W, Hooda J, Lucas PC, Atkinson JM, Oesterreich S, Lee AV. Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine. Ann Oncol 2022; 33:1085-1088. [PMID: 35764274 PMCID: PMC10007959 DOI: 10.1016/j.annonc.2022.06.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 05/04/2022] [Accepted: 06/17/2022] [Indexed: 11/26/2022] Open
Affiliation(s)
- K Ding
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA; Integrative Systems Biology Program, University of Pittsburgh, Pittsburgh, USA
| | - F Chen
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Tsinghua University, Beijing, China
| | - N Priedigkeit
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
| | - D D Brown
- Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, USA
| | - K Weiss
- Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA; Musculoskeletal Oncology Laboratory, University of Pittsburgh, Pittsburgh, USA
| | - R Watters
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA; Musculoskeletal Oncology Laboratory, University of Pittsburgh, Pittsburgh, USA
| | - K M Levine
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA
| | - T Heim
- Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA; Musculoskeletal Oncology Laboratory, University of Pittsburgh, Pittsburgh, USA
| | - W Li
- Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA
| | - J Hooda
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA
| | - P C Lucas
- Department of Pathology, University of Pittsburgh, Pittsburgh, USA
| | - J M Atkinson
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA; Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, USA
| | - S Oesterreich
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA.
| | - A V Lee
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA; Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, USA.
| |
Collapse
|
18
|
Cui Y, He Y, Hu C, Tu C, Huang J, Zhu X, Zang C, Ding K, Zhan B, Zhao Y, Qian L. Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial. Front Pharmacol 2022; 13:970978. [PMID: 36238568 PMCID: PMC9553127 DOI: 10.3389/fphar.2022.970978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Accepted: 08/29/2022] [Indexed: 11/13/2022] Open
Abstract
Objective: To explore the effect and safety of avatrombopag for chemotherapy-induced thrombocytopenia (CIT). Methods: This multicenter, open-label, single-arm trial enrolled CIT patients in eight centers from October 2020 to April 2021. The participants received avatrombopag tablets 60 mg once a day for 5–10 days. The main endpoint was the proportion of patients with platelet count ≥100×109/L or increased by ≥ 50×109/L or increased by ≥ 100% in the cycle after the start of treatment. Results: Seventy-four participants were enrolled with a mean age of 59.8 ± 11.62.2% were males. The cumulative effective rate (any criteria) was 70.3% at 4 weeks. 42 (56.8%) achieved platelet count ≥100×109/L, 44 (59.5%) increased by ≥ 50×109/L, and 27 (36.5%) increase by ≥ 100% from baseline. The duration of grade III and IV platelet reduction was 4.2 ± 5.3 days. The time of PLT recovery to ≥75×109/L was 9.4 ± 6.6 days. The time of PLT recovery to ≥100×109/L was 10.2 ± 6.4 days. The platelet count nadir was 57.9 ± 45.3×109/L. The most common adverse events were nausea (8.1%), fatigue (5.4%), and abdominal pain (1.4%). There were no cases of fever, headache, or peripheral edema. Conclusion: Although it was a single-arm trial without a control group, the application of avatrombopag in patients with CIT can increase the platelet count of the patients compared with baseline. Avatrombopag is safe and tolerable. Clinical Trial Registration:https://clinicaltrials.gov/ct2/show/NCT04609891?term=04609891&draw=2&rank=1, identifier [NCT04609891]
Collapse
Affiliation(s)
- Yayun Cui
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Yifu He
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Changlu Hu
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Congyin Tu
- Department of Surgical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Jin Huang
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Xiaofeng Zhu
- Department of Gastroenterology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Chunbao Zang
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Kaiyang Ding
- Department of Hematology-Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Bihong Zhan
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Yufei Zhao
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
| | - Liting Qian
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, Anhui, China
- *Correspondence: Liting Qian,
| |
Collapse
|
19
|
Akimov D, An P, Awe C, Barbeau P, Becker B, Belov V, Bernardi I, Blackston M, Bock C, Bolozdynya A, Bouabid R, Browning J, Cabrera-Palmer B, Chernyak D, Conley E, Daughhetee J, Detwiler J, Ding K, Durand M, Efremenko Y, Elliott S, Fabris L, Febbraro M, Gallo Rosso A, Galindo-Uribarri A, Green M, Heath M, Hedges S, Hoang D, Hughes M, Johnson B, Johnson T, Khromov A, Konovalov A, Kozlova E, Kumpan A, Li L, Link J, Liu J, Major A, Mann K, Markoff D, Mastroberti J, Mattingly J, Mueller P, Newby J, Parno D, Penttila S, Pershey D, Prior C, Rapp R, Ray H, Razuvaeva O, Reyna D, Rich G, Ross J, Rudik D, Runge J, Salvat D, Salyapongse A, Sander J, Scholberg K, Shakirov A, Simakov G, Snow W, Sosnovstsev V, Suh B, Tayloe R, Tellez-Giron-Flores K, Tolstukhin I, Ujah E, Vanderwerp J, Varner R, Virtue C, Visser G, Wongjirad T, Yen YR, Yoo J, Yu CH, Zettlemoyer J. COHERENT constraint on leptophobic dark matter using CsI data. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.106.052004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
20
|
Ding K, Liu Y, Song Y, Xu D, Li J, Wang J, Chen X, Lin R, Jiang Y, Zhang Y, Zhang W, Cheng Y, Wu X, Yuan Y. 441TiP A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
21
|
Liu L, Yu X, Li Z, He X, Zha J, Lin Z, Hong Y, Zheng H, Lai Q, Ding K, Jia X, Fu G, Yu H, Yang H, Li Z, Young KH, Xu B. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry. J Hematol Oncol 2022; 15:115. [PMID: 35996180 PMCID: PMC9396877 DOI: 10.1186/s13045-022-01326-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Accepted: 08/04/2022] [Indexed: 11/11/2022] Open
Abstract
Background Patients with follicular lymphoma (FL) who experience disease progression within 24 months (POD24) have inferior outcomes. The tumor immune microenvironment (TIME) plays a crucial role in pathogenesis and progression of follicular lymphoma (FL). However, TIME evolution during progression of disease within 24 months (POD24) is elusive. Methods Spatially resolved and single-cell image mass cytometry with a panel of 36 metal-tagged antibodies was used to quantitatively analyze the TIME structure in 13 paired FLs at diagnosis and POD24. Results Follicles and peri-follicular regions were well dissected in structure. Peri-follicular regions represented a barrier for immune infiltration into the follicles. More FL-cells in the peri-follicular regions suffered CD8+T cells attacks under simultaneous protection of regulatory T cells (Tregs) and/or macrophages compared with that in the follicles irrespective of POD24. During POD24, increased CD163− macrophages with PD-1 ligand upregulation and decreased CD8+T cells with upregulated LAG-3 expression around FL-cells were observed in the follicles. Spatial analyses demonstrated that FL-cells interacted more intimately with macrophages than with Tregs and less with cytotoxic T cells in both peri-follicular regions and follicles during POD24. In comparison, macrophages also cooperated more frequently with Tregs to simultaneously hijack FL-cells, creating an enhanced immunosuppressive environment in both peri-follicular and follicular regions during POD24. Conclusions Peri-follicular regions function as a barrier by recruiting both CD8+T cells and immunosuppressive cells, protecting follicular FL-cells from immune attack at diagnosis or POD24. FL-cells reside in a more immune-compromised microenvironment and evade immune cell attacks during POD24. Novel immunotherapeutic approaches harnessing LAG-3, macrophages, and Tregs will be empowered to overcome poor outcomes in patients with FL POD24. Supplementary Information The online version contains supplementary material available at 10.1186/s13045-022-01326-z.
Collapse
Affiliation(s)
- Long Liu
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, People's Republic of China
| | - Xingxing Yu
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, People's Republic of China
| | - Zhifeng Li
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, People's Republic of China
| | - Xiaohua He
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, People's Republic of China
| | - Jie Zha
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, People's Republic of China
| | - Zhijuan Lin
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, People's Republic of China
| | - Yan Hong
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, People's Republic of China
| | - Huijian Zheng
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, People's Republic of China
| | - Qian Lai
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, People's Republic of China
| | - Kaiyang Ding
- Department of Hematology, The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, 230001, People's Republic of China
| | - Xian Jia
- State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, 361005, People's Republic of China
| | - Guo Fu
- State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, 361005, People's Republic of China
| | - Haifeng Yu
- Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310012, People's Republic of China.,Department of Lymphoma, Institute of Cancer, and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, 310012, People's Republic of China
| | - Haiyan Yang
- Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310012, People's Republic of China.,Department of Lymphoma, Institute of Cancer, and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, 310012, People's Republic of China
| | - Zhiming Li
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, People's Republic of China.
| | - Ken H Young
- Hematopathology Division, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA. .,Duke University Cancer Institute, Durham, NC, USA.
| | - Bing Xu
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, People's Republic of China. .,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, 361003, People's Republic of China.
| |
Collapse
|
22
|
Akimov D, An P, Awe C, Barbeau PS, Becker B, Belov V, Bernardi I, Blackston MA, Bock C, Bolozdynya A, Browning J, Cabrera-Palmer B, Chernyak D, Conley E, Daughhetee J, Detwiler J, Ding K, Durand MR, Efremenko Y, Elliott SR, Fabris L, Febbraro M, Gallo Rosso A, Galindo-Uribarri A, Green MP, Heath MR, Hedges S, Hoang D, Hughes M, Johnson T, Khromov A, Konovalov A, Kozlova E, Kumpan A, Li L, Link JM, Liu J, Mann K, Markoff DM, Mastroberti J, Mueller PE, Newby J, Parno DS, Penttila SI, Pershey D, Rapp R, Ray H, Raybern J, Razuvaeva O, Reyna D, Rich GC, Ross J, Rudik D, Runge J, Salvat DJ, Salyapongse AM, Scholberg K, Shakirov A, Simakov G, Sinev G, Snow WM, Sosnovstsev V, Suh B, Tayloe R, Tellez-Giron-Flores K, Tolstukhin I, Ujah E, Vanderwerp J, Varner RL, Virtue CJ, Visser G, Wongjirad T, Yen YR, Yoo J, Yu CH, Zettlemoyer J. Measurement of the Coherent Elastic Neutrino-Nucleus Scattering Cross Section on CsI by COHERENT. Phys Rev Lett 2022; 129:081801. [PMID: 36053683 DOI: 10.1103/physrevlett.129.081801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Revised: 07/17/2022] [Accepted: 08/03/2022] [Indexed: 06/15/2023]
Abstract
We measured the cross section of coherent elastic neutrino-nucleus scattering (CEvNS) using a CsI[Na] scintillating crystal in a high flux of neutrinos produced at the Spallation Neutron Source at Oak Ridge National Laboratory. New data collected before detector decommissioning have more than doubled the dataset since the first observation of CEvNS, achieved with this detector. Systematic uncertainties have also been reduced with an updated quenching model, allowing for improved precision. With these analysis improvements, the COHERENT Collaboration determined the cross section to be (165_{-25}^{+30})×10^{-40} cm^{2}, consistent with the standard model, giving the most precise measurement of CEvNS yet. The timing structure of the neutrino beam has been exploited to compare the CEvNS cross section from scattering of different neutrino flavors. This result places leading constraints on neutrino nonstandard interactions while testing lepton flavor universality and measures the weak mixing angle as sin^{2}θ_{W}=0.220_{-0.026}^{+0.028} at Q^{2}≈(50 MeV)^{2}.
Collapse
Affiliation(s)
- D Akimov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - P An
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - C Awe
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - P S Barbeau
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - B Becker
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - V Belov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute," Moscow 117218, Russian Federation
| | - I Bernardi
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - M A Blackston
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - C Bock
- Physics Department, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - A Bolozdynya
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - J Browning
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | | | - D Chernyak
- Physics Department, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - E Conley
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - J Daughhetee
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Detwiler
- Center for Experimental Nuclear Physics and Astrophysics, Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - K Ding
- Physics Department, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - M R Durand
- Center for Experimental Nuclear Physics and Astrophysics, Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - Y Efremenko
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S R Elliott
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - L Fabris
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M Febbraro
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - A Gallo Rosso
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - A Galindo-Uribarri
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M P Green
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | - M R Heath
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S Hedges
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - D Hoang
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M Hughes
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - T Johnson
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - A Khromov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - A Konovalov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute," Moscow 117218, Russian Federation
| | - E Kozlova
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute," Moscow 117218, Russian Federation
| | - A Kumpan
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - L Li
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - J M Link
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - J Liu
- Physics Department, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - K Mann
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | - D M Markoff
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Mathematics and Physics, North Carolina Central University, Durham, North Carolina 27707, USA
| | - J Mastroberti
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - P E Mueller
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Newby
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - D S Parno
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S I Penttila
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - D Pershey
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - R Rapp
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - H Ray
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - J Raybern
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - O Razuvaeva
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute," Moscow 117218, Russian Federation
| | - D Reyna
- Sandia National Laboratories, Livermore, California 94550, USA
| | - G C Rich
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - J Ross
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Mathematics and Physics, North Carolina Central University, Durham, North Carolina 27707, USA
| | - D Rudik
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - J Runge
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - D J Salvat
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - A M Salyapongse
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - K Scholberg
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - A Shakirov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - G Simakov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
- Institute for Theoretical and Experimental Physics named by A.I. Alikhanov of National Research Centre "Kurchatov Institute," Moscow 117218, Russian Federation
| | - G Sinev
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - W M Snow
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - V Sosnovstsev
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Moscow 115409, Russian Federation
| | - B Suh
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - R Tayloe
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | | | - I Tolstukhin
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - E Ujah
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Mathematics and Physics, North Carolina Central University, Durham, North Carolina 27707, USA
| | - J Vanderwerp
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - R L Varner
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - C J Virtue
- Department of Physics, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
| | - G Visser
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - T Wongjirad
- Department of Physics and Astronomy, Tufts University, Medford, Massachusetts 02155, USA
| | - Y-R Yen
- Department of Physics, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - J Yoo
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Korea
| | - C-H Yu
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Zettlemoyer
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| |
Collapse
|
23
|
Akimov D, An P, Awe C, Barbeau P, Becker B, Belov V, Bernardi I, Blackston M, Bock C, Bolozdynya A, Browning J, Cabrera-Palmer B, Chernyak D, Conley E, Daughhetee J, Detwiler J, Ding K, Durand M, Efremenko Y, Elliott S, Fabris L, Febbraro M, Galambos J, Gallo Rosso A, Galindo-Uribarri A, Green M, Heath M, Hedges S, Hoang D, Hughes M, Iverson E, Johnson T, Khromov A, Konovalov A, Kozlova E, Kumpan A, Li L, Link J, Liu J, Mann K, Markoff D, Mastroberti J, McIntyre M, Mueller P, Newby J, Parno D, Penttila S, Pershey D, Rapp R, Ray H, Raybern J, Razuvaeva O, Reyna D, Rich G, Rimal D, Ross J, Rudik D, Runge J, Salvat D, Salyapongse A, Scholberg K, Shakirov A, Simakov G, Sinev G, Snow W, Sosnovstsev V, Suh B, Tayloe R, Tellez-Giron-Flores K, Tolstukhin I, Trotter S, Ujah E, Vanderwerp J, Varner R, Virtue C, Visser G, Wongjirad T, Yen YR, Yoo J, Yu CH, Zettlemoyer J, Zhang S. Simulating the neutrino flux from the Spallation Neutron Source for the COHERENT experiment. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.106.032003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
24
|
Song Y, Zhou K, Jin C, Qian Z, Hou M, Fan L, Li F, Ding K, Zhou H, Li X, Chen B, Sun X, Song X, Jiang M, Zhang Q, Liu L, Yu G, Hu Y, Zhao Z, Liu L, Xue H, Luo J, He B, Jin X, Zhao M, Li B, Xia Y, Zhu J. Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). Front Oncol 2022; 12:925236. [PMID: 35875118 PMCID: PMC9301139 DOI: 10.3389/fonc.2022.925236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 06/13/2022] [Indexed: 01/01/2023] Open
Abstract
Background Nearly all anti-PD-1 antibodies are of the IgG4 isotype, and thus possess residual FcR effector functions. Such anti-PD-1 antibodies are also associated with immune tolerance and escape due to instability of the CH3 domain and Fc-Fc interaction. In this trial, we examined the efficacy and safety of penpulimab, a novel IgG1 anti-PD-1 antibody that does not bind to the Fc receptor, in patients with refractory or relapsed classical Hodgkin lymphoma (R/R cHL). Methods Adult patients (≥18 years of age) with R/R cHL received 200 mg penpulimab once biweekly until disease progression or unacceptable toxicities for a maximum of 24 months. The primary endpoint was objective response rate (ORR) based on the Independent Radiology Review Committee per Lugano 2014 criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs). Results A total of 94 patients were enrolled. The median follow-up was 15.8 months. The ORR was 89.4% (95% CI 80.8%, 95.0%) in the full analysis set (85 patients). Forty (47.1%) patients achieved complete remission, 36 (42.4%) patients achieved partial remission. The 12-month PFS rate was 72.1% (95% CI 60.5%, 80.8%) and the 18-month OS rate was 100%. Totally 97.9% (92/94) of patients experienced at least one TRAE. The rate of grade 3 and above TRAEs was 26.6% (25/94). In addition, 51 (54.3%) patients experienced an irAE, and 4 (4.3%) patients developed grade 3 or above irAEs. No irAE-related death occurred. Conclusions Penpulimab was effective and safe in patients with R/R cHL.
Collapse
Affiliation(s)
- Yuqin Song
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - Keshu Zhou
- Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
| | - Chuan Jin
- Department of Oncology, Cancer Hospital Affiliated to Guangzhou Medical University, Guangzhou, China
| | - Zhengzi Qian
- Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
| | - Ming Hou
- Department of Hematology, Qilu Hospital, Shandong University, Jinan, China; Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Shandong University, Jinan, China
| | - Lei Fan
- Department of Hematology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China
| | - Fei Li
- Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Kaiyang Ding
- Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| | - Hui Zhou
- Lymphoma & Hematology Department, Tumor Hospital of Xiangya School of Medicine of Central South University, Changsha, China
| | - Xiaoling Li
- Department of Medical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, China
| | - Bing Chen
- Department of Hematology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China
| | - Xiuhua Sun
- Department of Medical Oncology, Second Affiliated Hospital of Dalian Medical University, Dalian, China
| | - Xianmin Song
- Department of Hematology, Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Ming Jiang
- Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Qingyuan Zhang
- Department of Medical Oncology, Heilongjiang Provincial Hospital, Harbin, China
| | - Lihong Liu
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Guohua Yu
- Clinical Oncology Department, Weifang People’s Hospital, Weifang, China
| | - Yu Hu
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zheng Zhao
- Third Department of Medical Oncology, Shaanxi Provincial Cancer Hospital, Xi’an, China
| | - Ligen Liu
- Department of Hematology, Shanghai Tongren Hospital, Shanghai, China
| | - Hongwei Xue
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Jun Luo
- Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Bai He
- Department of Hematology, The Third Affiliated Hospital of Suzhou University, The First People’s Hospital of Changzhou, Changzhou, China
| | | | - Min Zhao
- Akeso Biopharma Co., Ltd., Zhongshan, China
| | - Baiyong Li
- Akeso Biopharma Co., Ltd., Zhongshan, China
| | - Yu Xia
- Akeso Biopharma Co., Ltd., Zhongshan, China
| | - Jun Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
- *Correspondence: Jun Zhu,
| |
Collapse
|
25
|
Jackson CG, Moore KN, Cantrell L, Erickson BK, Duska LR, Richardson DL, Landrum LM, Holman LL, Walker JL, Mannel RS, Moxley KM, Queimado L, Cohoon A, Ding K, Dockery LE. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol 2022; 166:44-49. [PMID: 35491267 PMCID: PMC10428664 DOI: 10.1016/j.ygyno.2022.04.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 04/17/2022] [Accepted: 04/19/2022] [Indexed: 11/22/2022]
Abstract
OBJECTIVE The aim of this study was to examine the tolerability and efficacy of combination bevacizumab rucaparib therapy in patients with recurrent cervical or endometrial cancer. PATIENTS & METHODS Thirty-three patients with recurrent cervical or endometrial cancer were enrolled. Patients were required to have tumor progression after first line treatment for metastatic, or recurrent disease. Rucaparib was given at 600 mg BID twice daily for each 21-day cycle. Bevacizumab was given at 15 mg/kg on day 1 of each 21-day cycle. The primary endpoint was efficacy as determined by objective response rate or 6-month progression free survival. RESULTS Of the 33 patients enrolled, 28 were evaluable. Patients with endometrial cancer had a response rate of 17% while patients with cervical cancer had a response rate of 14%. Median progression free survival was 3.8 months (95% C·I 2.5 to 5.7 months), and median overall survival was 10.1 months (95% C·I 7.0 to 15.1 months). Patients with ARID1A mutations displayed a better response rate (33%) and 6-month progression free survival (PFS6) rate (67%) than the entire study population. Observed toxicity was similar to that of previous studies with bevacizumab and rucaparib. CONCLUSIONS The combination of bevacizumab with rucaparib did not show significantly increased anti-tumor activity in all patients with recurrent cervical or endometrial cancer. However, patients with ARID1A mutations had a higher response rate and PFS6 suggesting this subgroup may benefit from the combination of bevacizumab and rucaparib. Further study is needed to confirm this observation. No new safety signals were seen.
Collapse
Affiliation(s)
- C G Jackson
- Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - K N Moore
- Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - L Cantrell
- Division of Gynecologic Oncology, University of Virginia, Department of Obstetrics and Gynecology; Charlottesville, VA, USA
| | - B K Erickson
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Minnesota; Minneapolis, MN, USA
| | - L R Duska
- Division of Gynecologic Oncology, University of Virginia, Department of Obstetrics and Gynecology; Charlottesville, VA, USA
| | - D L Richardson
- Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - L M Landrum
- Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - L L Holman
- Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - J L Walker
- Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - R S Mannel
- Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - K M Moxley
- Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - L Queimado
- Department of Otolaryngology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - A Cohoon
- Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - K Ding
- Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center; Oklahoma City, OK, USA
| | - L E Dockery
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina; Chapel Hill, NC, USA.
| |
Collapse
|
26
|
Sang CM, Shi QL, Kang YJ, Cui LM, Ding K, Liu XQ, Zhao SP. [Pregnancy outcomes in patients with adenomyosis with fertility requirements: retrospective analysis of clinical data from real world]. Zhonghua Fu Chan Ke Za Zhi 2022; 57:265-270. [PMID: 35484658 DOI: 10.3760/cma.j.cn112141-20210830-00475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To retrospectively analyze the pregnancy outcomes of patients with adenomyosis requiring fertility in a single center under real world condition. Methods: From June 2015 to May 2020, 231 cases of pregnancy complicated with adenomyosis diagnosed by ultrasound with fertility requirements were treated in the Women's and Children's Hospital Affiliated to Qingdao University with complete clinical data. And they were divided into three groups according to the treatment of adenomyosis before pregnancy: expectation group, drug group and operation group. The relevant data before pregnancy of the three groups were analyzed, and the pregnancy outcomes of the patients were summarized. According to whether the early pregnancy was treated with medication, the patients who were naturally conceived without symptoms of threatened abortion were divided into observation group and fetus protection group, and the pregnancy outcomes of the two groups were compared. Results: (1) Compared with the expectation group, the ages of patients in the drug group and the operation group were larger [(31.5±1.8) vs (34.1±3.7) vs (36.9±3.6) years old], and the difference was statistically significant (P<0.05). Only 9 patients (11.5%, 9/78) had clinical symptoms in the expectation group, while the patients in the drug group and the operation group had a higher proportion of dysmenorrhea and increased menstrual volume. The uterine volume of the drug group and the operation group were larger than that of the expectation group [(151±46) vs (166±27) vs (97±18) cm3], the difference was statistically significant (P<0.05). 78.6% (33/42) of the operation group were focal adenomyosis. The proportion of natural pregnancy in the expectation group was 97.4% (76/78), and in vitro fertilization and embryo transfer was mainly used in the drug group and the operation group. (2) The abortion rates of the three groups were 48.7% (26/111), 4/17, 67.5% (27/78) respectively. Compared with the drug group and the operation group, the preterm birth rate was lower [55.9% (33/111) vs 11/17 vs 12.5% (5/78)] and the natural delivery rate was higher [44.1% (26/111) vs 4/17 vs 67.5% (27/78)] in the expectation group. (3) There were 89 cases of spontaneous pregnancy without threatened abortion symptoms, including 31 cases in the observation group and 58 cases in the fetus protection group. Compared with the observation group, the abortion rate of patients in the fetus protection group was lower [41.9% (13/31) vs 34.5% (20/58)], and the difference was statistically significant (P<0.05). Conclusions: Patients with adenomyosis who have fertility requirements should be comprehensively evaluated and individualized treatment plans should be given. Pregnancy patients with adenomyosis have a high rate of miscarriage, and they should be included in the management of high-risk pregnant women. Active fetal protection treatment during early pregnancy might improve pregnancy outcomes.
Collapse
Affiliation(s)
- C M Sang
- Center for Gynecology, Women's and Children's Hospital Affiliated to Qingdao University, Qingdao 266011, China
| | - Q L Shi
- State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China
| | - Y J Kang
- Center for Gynecology, Women's and Children's Hospital Affiliated to Qingdao University, Qingdao 266011, China
| | - L M Cui
- Department of Gynecology, Qingzhou Hospital Affiliated to Shandong First Medical University, Weifang 262500, China
| | - K Ding
- Center for Gynecology, Women's and Children's Hospital Affiliated to Qingdao University, Qingdao 266011, China
| | - X Q Liu
- Center for Reproduction, Women's and Children's Hospital Affiliated to Qingdao University, Qingdao 266011, China
| | - S P Zhao
- Center for Gynecology, Women's and Children's Hospital Affiliated to Qingdao University, Qingdao 266011, China
| |
Collapse
|
27
|
Wang X, Hu M, Yu L, Wang X, Jiang X, Zhang G, Ding K. The "m6A writer" METTL3 and the "m6A reader" IGF2BP2 regulate cutaneous T-cell lymphomas (CTCL) progression via CDKN2A. Hematol Oncol 2022; 40:567-576. [PMID: 35446451 DOI: 10.1002/hon.3005] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2021] [Revised: 04/05/2022] [Accepted: 04/07/2022] [Indexed: 11/08/2022]
Abstract
It has been established that Cutaneous T-Cell lymphomas (CTCL) are caused by the monoclonal proliferation of T lymphocytes in the skin. This heterogeneous group of diseases represents a significant source of distress to patients since the diagnosis and treatment are often challenging. As one of the most abundant internal modifications in mRNA in higher eukaryotes, N6-methyladenosine (m6A) is widely recognized to affect the development and progression of cancers. However, knowledge on the involvement of m6A in CTCL is still limited. In this work, we revealed the role of METTL3-mediated m6A modification in CTCL progression. ELISA, western blot, and qRT-PCR assays demonstrated that METTL3 was significantly downregulated in CTCL cells both in vivo and in vitro. CCK-8, EdU, flow cytometry, and transwell assays showed that the decline in METTL3 levels was responsible for CTCL cell proliferation and migration. Furthermore, using small interfering RNAs (siRNAs) against METTL3 and the RIP assay, we showed that CDKN2A was a key regulator during this process in vitro and in vivo, and insufficient methylation modification blocked the interaction between CDKN2A and m6A reader IGF2BP2, resulting in mRNA degradation. To the best of our knowledge, this is the first study to depict the role of m6A in CTCL development and provide potential bio-targets for therapy. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Xinchen Wang
- Department of Hematology, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, 230001, China
| | - Maogui Hu
- Department of Hematology, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, 230001, China
| | - Lu Yu
- Department of Hematology, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, 230001, China
| | - Xiaoyan Wang
- Department of Hematology, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, 230001, China
| | - Xinlu Jiang
- Department of Hematology, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, 230001, China
| | - Guihong Zhang
- Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China
| | - Kaiyang Ding
- Department of Hematology, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, 230001, China
| |
Collapse
|
28
|
Ding K, Yu L, Huang Z, Zheng H, Yang X, Tian T, Xie R. [Differential expression profile of miRNAs in amniotic fluid exosomes from fetuses with Down syndrome]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:293-299. [PMID: 35365456 DOI: 10.12122/j.issn.1673-4254.2022.02.18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the role of miRNAs in amniotic fluid exosomes in growth and development of fetuses with Down syndrome (DS). METHODS Amniotic fluid were collected from 20 fetuses with DS and 20 normal fetuses (control) to extract amniotic exosome miRNA. MicroRNA sequencing technique was used to identify the differentially expressed miRNAs between the two groups, for which gene ontology (GO) and pathway analysis was performed. Three differentially expressed miRNAs with the strongest correlation with DS phenotype were selected for qPCR verification. Dual luciferase reporter assay was used to verify the activity of let-7d-5p for targeted regulation of BACH1. RESULTS We identified 15 differentially expressed miRNAs in DS as compared with the control group, among which 7 miRNAs were up-regulated and 8 were down-regulated. Target gene prediction results showed that the differentially expressed miRNAs targeted 17 DS-related genes. GO analysis revealed that the main functions of the target genes involved protein binding, protein transport, ATP binding, transferase activity and synapses. Pathway analysis revealed that the functional pathways were closely related with the development of the nervous system. qPCR results showed that the expression levels of miR-140-3p and let-7d-5p were significantly lower in DS group than in the control group (P < 0.05), as was consistent with miRNA sequencing results; the expression level of miR-4512 was significantly higher in DS group than in control group (P < 0.05), which was contrary to miRNA sequencing results. The results of double luciferase reporter gene assay confirmed that let-7d-5p was capable of targeted regulation of BACH1 expression. CONCLUSION Let-7d-5p in amniotic fluid exosomes may promote oxidative stress events in the brain of fetuses with DS by regulating BACH1 expression.
Collapse
Affiliation(s)
- K Ding
- Department of Pathophysiology, Guizhou Medical University, Guiyang 550025, China.,Department of Assisted Reproduction, Guiyang Maternal and Child Health Care Center, Guiyang 550003, China
| | - L Yu
- Department of Pathology, Guiyang Maternal and Child Health Care Center, Guiyang 550003, China
| | - Z Huang
- Department of Eugenic Genetics, Guiyang Maternal and Child Health Care Center, Guiyang 550003, China
| | - H Zheng
- Department of Eugenic Genetics, Guiyang Maternal and Child Health Care Center, Guiyang 550003, China
| | - X Yang
- Department of Eugenic Genetics, Guiyang Maternal and Child Health Care Center, Guiyang 550003, China
| | - T Tian
- Department of Eugenic Genetics, Guiyang Maternal and Child Health Care Center, Guiyang 550003, China
| | - R Xie
- Department of Pathophysiology, Guizhou Medical University, Guiyang 550025, China
| |
Collapse
|
29
|
Ding K, Wang X, Hu K, Wang L, Wu G, Ni K, Zhou Q. Three-dimensional morphology measurement of underwater objects based on the photoacoustic effect. Opt Lett 2022; 47:641-644. [PMID: 35103693 DOI: 10.1364/ol.446277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 12/09/2021] [Indexed: 06/14/2023]
Abstract
Complexities of the underwater environment can seriously affect many underwater detection means, especially the influence of light scattering by water. To solve this problem, a three-dimensional (3D) morphology measurement method is proposed based on the photoacoustic effect. In this method, a measurement object is irradiated with pulsed laser light to produce ultrasonic waves via the photoacoustic effect. A probe collects the ultrasonic signal and subsequent data processing can yield complete object detection. This approach can make full use of the advantages of high precision and good directivity of laser ranging and completely avoid the influence on the laser of backscattering from water. The results yield a displacement measurement accuracy of less than 0.5 mm and an average error of 3D reconstruction of 0.21 mm, demonstrating great application potential.
Collapse
|
30
|
Liu W, Zhao D, Liu T, Niu T, Song Y, Xu W, Jin J, Cai Q, Huang H, Li Z, Hou M, Zhang H, Zhou J, Hu J, Shen J, Shi Y, Yang Y, Zhang L, Zhao W, Ding K, Qiu L, Tan H, Zhang Z, Liu L, Wang J, Xu B, Zhou H, Gao G, Xue H, Bai O, Feng R, Huang X, Yang H, Yan X, Zeng Q, Liu P, Li W, Mao M, Su H, Wang X, Xu J, Zhou D, Zhang H, Ma J, Shen Z, Zhu J. A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. Front Oncol 2021; 11:750323. [PMID: 34804937 PMCID: PMC8602952 DOI: 10.3389/fonc.2021.750323] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Accepted: 10/15/2021] [Indexed: 02/05/2023] Open
Abstract
Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December 2017, 548 patients with R/R PTCL from 186 research centers in China were included in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 patients receiving chidamide-containing combination therapies, ORR was 73.2% and 73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. The median OS of patients receiving chidamide monotherapy and combination therapies was 433 and 463 days, respectively. These results demonstrate a significant survival advantage of chidamide treatments as compared with international historical records. Common adverse effects (AEs) were hematological toxicities. Most AEs in both monotherapy and combined treatments were grade 1–2. No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a favorable efficacy and survival benefit for R/R PTCL. Future studies should explore the potential advantage of chidamide treatment combined with chemotherapy.
Collapse
Affiliation(s)
- Weiping Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China
| | - Donglu Zhao
- Department of Hematology and Oncology, Harbin Institute of Hematology and Oncology, Harbin, China
| | - Ting Liu
- Department of Hematology, West China Hospital Sichuan University, Chengdu, China
| | - Ting Niu
- Department of Hematology, West China Hospital Sichuan University, Chengdu, China
| | - Yongping Song
- Department of Hematology, Henan Cancer Hospital, Zhengzhou, China
| | - Wei Xu
- Department of Hematology, Jiangsu Province Hospital, Nanjing, China
| | - Jie Jin
- Department of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China
| | - Qingqing Cai
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Huiqiang Huang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Zhiming Li
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Ming Hou
- Department of Hematology, Qilu Hospital Shandong University, Jinan, China
| | - Huilai Zhang
- Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Jianfeng Zhou
- Department of Hematology, Tongji Hospital Huazhong University of Science and Technology, Wuhan, China
| | - Jianda Hu
- Department of Hematology, The Affiliated Union Hospital of Fujian Medical University, Fuzhou, China
| | - Jianzhen Shen
- Department of Hematology, The Affiliated Union Hospital of Fujian Medical University, Fuzhou, China
| | - Yuankai Shi
- Department of Medical Oncology, The Cancer Institute and Hospital Chinese Academy of Medical Sciences, Beijing, China
| | - Yu Yang
- Department of Lymphoma, Fujian Cancer Hospital, Fuzhou, China
| | - Liling Zhang
- Department of Medical Oncology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
| | - Weili Zhao
- Department of Hematology, Shanghai Rui Jin Hospital, Shanghai, China
| | - Kaiyang Ding
- Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China
| | - Lugui Qiu
- Department of Hematology, The Hematology Institute and Hospital Chinese Academy of Medical Sciences, Tianjin, China
| | - Huo Tan
- Department of Hematology, The First Affiliated Hospital Guangzhou Medical University, Guangzhou, China
| | - Zhihui Zhang
- Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China
| | - Lihong Liu
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Jinghua Wang
- Department of Medical Oncology, Nanjing General Hospital of Nanjing Military Command, Nanjing, China
| | - Bing Xu
- Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China
| | - Hui Zhou
- Department of Lymphoma, Hunan Cancer Hospital, Changsha, China
| | - Guangxun Gao
- Department of Hematology, Xijing Hospital of Airforce Medical University, Xi'an, China
| | - Hongwei Xue
- Department of Lymphoma, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Ou Bai
- Department of Hematology, The First Bethune Hospital of Jilin University, Changchun, China
| | - Ru Feng
- Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, China
| | - Xiaobing Huang
- Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
| | - Haiyan Yang
- Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou, China
| | - Xiaojing Yan
- Department of Hematology, The First Hospital of China Medical University, Shenyang, China
| | - Qingshu Zeng
- Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, China
| | - Peng Liu
- Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China
| | - Wenyu Li
- Department of Lymphoma, Guangdong Provincial People's Hospital, Guangzhou, China
| | - Min Mao
- Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumchi, China
| | - Hang Su
- Department of Lymphoma, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China
| | - Xin Wang
- Department of Hematology, Shandong First Medical University Affiliated Provincial Hospital, Jinan, China
| | - Jingyan Xu
- Department of Hematology, Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - Daobin Zhou
- Department of Hematology, Peking Union Medical College Hospital, Beijing, China
| | - Hongyu Zhang
- Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Jun Ma
- Department of Hematology and Oncology, Harbin Institute of Hematology and Oncology, Harbin, China
| | - Zhixiang Shen
- Department of Hematology, Shanghai Rui Jin Hospital, Shanghai, China
| | - Jun Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China
| |
Collapse
|
31
|
Ding K, Liu Y, Du J, Zhu Y, Xu D, Li J, Liao X, He J, Wang J, Liu Z, Sun L, Xiao Q, Wang J, Cao H, Cai Y, Cai C, Jin Z, Yuan Y. 420P A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Zha J, Fan L, Yi S, Yu H, Zheng Z, Xu W, Deng M, Lin Z, Li Z, Ping L, He X, Chen F, Xie Y, Chen B, Zhang H, Wang L, Ding K, Li W, Yang H, Zhao W, Qiu L, Li Z, Song Y, Xu B. Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China. J Hematol Oncol 2021; 14:131. [PMID: 34425858 PMCID: PMC8383436 DOI: 10.1186/s13045-021-01139-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Accepted: 08/10/2021] [Indexed: 11/10/2022] Open
Abstract
Clinical features and outcomes of FL patients in Chinese population are limited, thus promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled from nine medical centers nationwide in China. In this cohort, the median age of patients at diagnosis was 53 years, which was comparable to that reported previously for Chinese FL patients (49-51 years) but younger than that for Western FL patients (60-65 years). In contrast with Western patients, Chinese FL patients more likely involved extranodal sites but less frequently infiltrated bone marrow. Other clinical characteristics were comparable between two populations. In this study, 91% of patients were managed with chemotherapy, yielding 72% and 46% of overall-response rate and complete remission. After median 55-month follow-up, 5-year progressive-free and overall survival were 61% and 89%, respectively. Both were analogous to those reported in prior Chinese and Western studies. Consistent with published data, addition of rituximab into both induction (Ri) and maintenance (Rm) treatment led to the most favorable outcomes. Interestingly, Ri only had better outcomes than Rm only. Notably, 7% of patients experienced histologic transformation (HT) and correlated with poor survival. Of the transformed FL cases, 3% and 4% of HT events occurred prior to or post-treatment, respectively. Importantly, the latter displayed worse outcomes than the former. Altogether, this study provides real-world information of the largest cohort of FL patients so far in China, which might lay a foundation for clinical investigation of Chinese FL in future.
Collapse
Affiliation(s)
- Jie Zha
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China
| | - Liyuan Fan
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China
| | - Shuhua Yi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital and Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Haifeng Yu
- Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.,Department of Lymphoma, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China
| | - Zhong Zheng
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Wei Xu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
| | - Manman Deng
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China
| | - Zhijuan Lin
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China
| | - Zhifeng Li
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China
| | - Lingyan Ping
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China
| | - Xiaohua He
- Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.,State Key Laboratory of Oncology in South China, Guangzhou, China.,Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Feili Chen
- Lymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Ying Xie
- Shengli Clinical Medical College of Fujian Medical University, Department of Hematology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China
| | - Biyun Chen
- Shengli Clinical Medical College of Fujian Medical University, Department of Hematology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China
| | - Huilai Zhang
- Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin, China
| | - Li Wang
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
| | - Kaiyang Ding
- Department of Hematology, The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, China
| | - Wenyu Li
- Lymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Haiyan Yang
- Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.,Department of Lymphoma, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China
| | - Weili Zhao
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Lugui Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital and Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Zhiming Li
- Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. .,State Key Laboratory of Oncology in South China, Guangzhou, China. .,Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
| | - Yuqin Song
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
| | - Bing Xu
- Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China. .,Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China.
| |
Collapse
|
33
|
Fomra D, Mamun M, Ding K, Avrutin V, Özgür Ü, Kinsey N. Plasmonic colors in titanium nitride for robust and covert security features. Opt Express 2021; 29:19586-19592. [PMID: 34266066 DOI: 10.1364/oe.423155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Accepted: 06/01/2021] [Indexed: 06/13/2023]
Abstract
A mechanically robust metasurface exhibiting plasmonic colors across the visible and the near-IR spectrum is designed, fabricated, and characterized. Thin TiN layers (41 nm in thickness) prepared by plasma-enhanced atomic layer deposition (ALD) are patterned with sub-wavelength apertures (75 nm to 150 nm radii), arranged with hexagonal periodicity. These patterned films exhibit extraordinary transmission in the visible and the near-IR spectrum (550 nm to 1040 nm), which is accessible by conventional Si CCD detectors. The TiN structures are shown to withstand high levels of mechanical stresses, tested by rubbing the films against a lint-free cloth under 14.5 kPa of load for 30 minutes, while structures patterned on gold, a widely used plasmonic material, do not. The subwavelength nature of the plasmonic resonances, coupled with robustness and durability of TiN, makes these structures an attractive choice for use in nanoscale security features for heavily handled objects. Furthermore, ALD of these films enables scalability, which in conjunction with the cost-effectiveness of the process and material (TiN) makes the entire process industry friendly.
Collapse
|
34
|
Xu W, Song Y, Wang T, Yang S, Liu L, Hu Y, Zhang W, Zhou J, Gao S, Ding K, Zhang H, Zhu Z, Wang S, Xu B, Hu J, Liu T, Ji C, Xia Z, Li Y, Wang X, Zhao R, Zhang B, Li J. UPDATED EFFICACY AND SAFETY RESULTS OF ORELABRUTINIB IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL CELL LEUKEMIA. Hematol Oncol 2021. [DOI: 10.1002/hon.43_2880] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- W. Xu
- Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Hematology Department Nanjing China
| | - Y. Song
- Affiliated Cancer Hospital of Zhengzhou University Hematology Department Zhengzhou China
| | - T. Wang
- National Clinical Research Center for Blood Disease State Key Laboratory of Experimental Hematology, Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Lymphoma Center Tianjin China
| | - S. Yang
- Peking University People's Hospital Hematology Department Beijing China
| | - L. Liu
- The Fourth Hospital of Hebei Medical University Hematology Department Shijiazhuang China
| | - Y. Hu
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Hematology Department Wuhan China
| | - W. Zhang
- Peking Union Medical College Hospital Hematology Department Beijing China
| | - J. Zhou
- Tongji Hospital Huazhong University of Science and Technology Hematology Department Wuhan China
| | - S. Gao
- The First Hospital, Jilin University Hematology Department Jilin China
| | - K. Ding
- The First Affiliated Hospital of University of Science and Technology of China Hematology Department Hefei China
| | - H. Zhang
- Tianjin Medical University Cancer Institute & Hospital Lymphoma Tianjin China
| | - Z. Zhu
- Henan Provincial People's Hospital Hematology Department Zhengzhou China
| | - S. Wang
- Guangzhou First People's Hospital Hematology Department Guangzhou China
| | - B. Xu
- The First Affiliated Hospital of Xiamen University Hematology Department Xiamen China
| | - J. Hu
- Fujian Medical University Union Hospital, Fujian Institute of Hematology Fujian Provincial Key Laboratory on Hematology, Hematology Department Fuzhou China
| | - T. Liu
- West China Hospital Sichuan University Hematology Department Chengdu China
| | - C. Ji
- Qilu Hospital, Cheeloo College of Medicine Shandong University Hematology Department Jinan China
| | - Z. Xia
- Sate Key Laboratory of Oncology in South China, Collaborative Innovation of Cancer Medicine Sun Yat‐sen University Cancer center Department of Hematologic Oncology Guangzhou China
| | - Y. Li
- The First Affiliated Hospital of China Medical University Hematology Department Shenyang China
| | - X. Wang
- School of Medicine Shandong University Hematology Jinan China
| | - R. Zhao
- Beijing InnoCare Pharma Tech Co., Ltd Beijing China
| | - B. Zhang
- Beijing InnoCare Pharma Tech Co., Ltd Beijing China
| | - J. Li
- Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Hematology Department Nanjing China
| |
Collapse
|
35
|
Song Y, Zhou K, Jin C, Qian Z, Hou M, Fan L, Li F, Ding K, Zhou H, Li X, Chen B, Sun X, Song X, Jiang M, Zhang Q, Jin X, Wang ZM, Li B, Xia Y, Zhu J. A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL). J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.7529] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
7529 Background: Penpulimab is a humanized IgG1 monoclonal antibody (mAb) that blocks PD-1 binding to PD-L1. Penpulimab, with its unique binding epitope, was engineered to eliminate Fc-mediated effector function that compromises anti-tumor immune cell function, and to optimize receptor occupancy by improving duration of drug binding. Fc-mediated effector functions, such as ADCC/ADCP, have been observed in most IgG4 anti-PD-1 mAbs but is absent in penpulimab, thereby potentially reducing the occurrence of immune-related adverse reactions. Penpulimab also demonstrated a slower PD-1 antigen binding off-rate than marketed anti-PD-1 mAbs, thereby resulting in better cellular activity and higher receptor occupancy. Penpulimab’s numerous contacts with N58 glycosylation on the BC loop of PD-1 may also contribute to a slower binding off-rate. These structural differentiations of penpulimab enhance its anti-tumor activity and produce a superior safety profile. Methods: AK105-201 is a multicenter, single-arm, open-label study of penpulimab in relapsed/refractory (R/R) cHL. All pts received penpulimab 200 mg Q2W until progression or unacceptable toxicity. Eligible pts had prior autologous stem cell transplant (ASCT) or at least 2 lines of prior chemotherapy. The primary endpoint was ORR based on the Lugano 2014 criteria as assessed by an independent review committee (IRC). Key secondary endpoints included CR rate, DCR, PFS, duration of response (DoR), safety, and tolerability. Results: As of 8 November 2020, of 94 pts (59.6% male, median age 32.0 yrs [31-71], 26.6% was ECOG 1) enrolled, 56 pts remained on treatment, 4 pts completed 24-months treatment and 25 had discontinued (17 due to disease progression, 3 due to AE). After a median follow-up of 15.8 months, the IRC-assessed ORR in the 85 pts evaluable for efficacy was 89.4% (95% CI: 80.8%, 95.0%). A total of 40 patients (47.1%) achieved CR. Median duration of response was not reached with range from 1.7 to 24.5+ months. Median PFS was not reached with 12-months PFS rate was 72.1% ( 95% CI: 60.5%, 80.8%). Treatment-related adverse events (TRAEs, with unlikely-related events included) occurred in 97.9% of pts ( ≥ G3 in 26.6% [25/94], treatment discontinuation in 5.3% [5/94]). Treatment-related SAEs occurred in 10.6%. Most frequent TRAEs (≥20%) were hypothyroidism (31.9%), upper respiratory tract infection (25.5%), fever (24.5%), and ALT elevations (23.4%). Grade ≥3 TRAEs reported in ≥2 pts were platelet count decreased (3.2%), hyperlipemia (3.2%), rash (3.2%), neutrophil count decreased (2.1%). Grade 3 immune-related AEs (irAEs) were reported in 4.3%: IgA nephropathy, pneumonitis, rash, psoriasis (each n = 1) and no G4 or G5 irAEs reported. Conclusions: Penpulimab was shown to be highly active in achieving in a CR rate of 47.1% in pts with R/R cHL while demonstrating lower rates of SAEs, TRAEs leading to discontinuation, and Grade ≥3 irAEs. Clinical trial information: NCT03722147.
Collapse
Affiliation(s)
- Yuqin Song
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Bejing, China
| | - Keshu Zhou
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
| | - Chuan Jin
- Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China
| | - Zhengzi Qian
- Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
| | - Ming Hou
- Qilu Hospital of Shandong University, Jinan, China
| | - Lei Fan
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China
| | - Fei Li
- The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Kaiyang Ding
- Department of Haematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
| | - Hui Zhou
- Hunan Cancer Hospital the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - Xiaoling Li
- Liaoning Province Cancer Hospital, Shenyang, China
| | - Bing Chen
- Department of Hematology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China
| | - Xiuhua Sun
- Department of Oncology, Second Hospital of Dalian Medical University, Dalian, China
| | - Xianmin Song
- Department of Hematology, Shanghai First People’s Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Ming Jiang
- West China Hospital, Sichuan University, Chengdu, China
| | - Qingyuan Zhang
- Harbin Medical University Cancer Hospital, Harbin, China
| | | | | | | | - Yu Xia
- Akeso Biopharma, Inc., Zhongshan, China
| | - Jun Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| |
Collapse
|
36
|
Wang X, Zhou Y, Ding K. Roles of exosomes in cancer chemotherapy resistance, progression, metastasis and immunity, and their clinical applications (Review). Int J Oncol 2021; 59:44. [PMID: 34013358 PMCID: PMC8143748 DOI: 10.3892/ijo.2021.5224] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 04/21/2021] [Indexed: 12/18/2022] Open
Abstract
Exosomes are a type of vesicle that are secreted by cells, with a diameter of 40-100 nm, and that appear as a cystic shape under an electron microscope. Exosome cargo includes a variety of biologically active substances such as non-coding RNA, lipids and small molecule proteins. Exosomes can be taken up by neighboring cells upon secretion or by distant cells within the circulatory system, affecting gene expression of the recipient cells. The present review discusses the formation and secretion of exosomes, and how they can remodel the tumor microenvironment, enhancing cancer cell chemotherapy resistance and tumor progression. Exosome-mediated induction of tumor metastasis is also highlighted. More importantly, the review discusses the manner in which exosomes can change the metabolism of cancer cells and the immune system, which may help to devise novel therapeutic approaches for cancer treatment. With the development of nanotechnology, exosomes can also be used as biomarkers and for the delivery of chemical drugs, serving as a tool to diagnose and treat cancer.
Collapse
Affiliation(s)
- Xiaoyan Wang
- Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, P.R. China
| | - Yuan Zhou
- Gruduate School, Tianjin Medical University, Tianjin 300070, P.R. China
| | - Kaiyang Ding
- Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, P.R. China
| |
Collapse
|
37
|
Li W, Cheng P, Zhang JB, Zhao LM, Ma YB, Ding K. Synergism of microorganisms and enzymes in solid-state fermentation of animal feed. A review. J Anim Feed Sci 2021. [DOI: 10.22358/jafs/133151/2021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
38
|
Liu W, Li Y, Wang Q, Su H, Ding K, Shuang Y, Gao S, Zou D, Jing H, Chai Y, Zhang Y, Liu L, Wang C, Liu H, Lin J, Zhu H, Yao C, Yan X, Shang M, Wang S, Chang F, Wang X, Zhu J, Song Y. YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial. Front Med (Lausanne) 2021; 8:609116. [PMID: 33604348 PMCID: PMC7884449 DOI: 10.3389/fmed.2021.609116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Accepted: 01/04/2021] [Indexed: 12/14/2022] Open
Abstract
Background: YF-H-2015005, a novel CXCR4 antagonist, has been proven to increase the quantities of circulating hematopoietic stem cells (HSCs), which results in an adequate collection of HSCs in non-Hodgkin lymphoma (NHL) patients. Methods: This was a multicenter, double-blind, randomized (1:1), placebo-controlled phase III clinical trial. All patients received granulocyte colony-stimulating factor (G-CSF) for up to 8 consecutive days. YF-H-2015005 or placebo was administrated on the evening of day 4 and continued daily for up to 4 days. Apheresis was conducted 9–10 h after each dose of YF-H-2015005 or placebo. The primary endpoint was the proportion of NHL patients procuring ≥5 × 106/kg CD34+ HSCs within ≤4 apheresis sessions. Results: In total, 101 patients with NHL were enrolled. The proportions of patients achieving primary endpoint were 57 and 12% in YF-H-2015005 and placebo groups, respectively (P < 0.001). Moreover, a higher proportion of YF-H-2015005-treated patients reached a minimum target collection of ≥2 × 106/kg CD34+ HSCs in ≤4 apheresis days compared to placebo-treated patients (86 vs. 38%, P < 0.001). Furthermore, the median time to collect ≥2 or 5 × 106/kg CD34+ HSCs were 1 and 3 days in YF-H-2015005-treated patients, but 4 days and not reached in placebo-treated patients, respectively. No severe treatment emergent adverse events were observed in both YF-H-2015005 treatment and placebo groups. Conclusions: YF-H-2015005 plus G-CSF regimen was a tolerable combination with high efficacy, which might be used to rapidly mobilize and collect HSCs in NHL patients.
Collapse
Affiliation(s)
- Weiping Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - Yufu Li
- Department of Hematology, Henan Cancer Hospital, Zhengzhou, China
| | - Quanshun Wang
- Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Hang Su
- Department of Lymphoma, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Kaiyang Ding
- Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China
| | - Yuerong Shuang
- Department of Lymphoma & Hematology, Jiangxi Cancer Hospital, Nanchang, China
| | - Sujun Gao
- Department of Hematology, First Affiliated Hospital of Jilin University, Changchun, China
| | - Dehui Zou
- Department of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
| | - Hongmei Jing
- Department of Hematology, Peking University Third Hospital, Beijing, China
| | - Ye Chai
- Department of Hematology, Lanzhou University Second Hospital, Lanzhou, China
| | - Yicheng Zhang
- Department of Hematology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Lihong Liu
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Chunling Wang
- Department of Hematology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, China
| | - Hui Liu
- Department of Hematology, Beijing Hospital, Beijing, China
| | - Jinying Lin
- Department of Hematology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
| | - Haiyan Zhu
- Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Chen Yao
- Department of Medical Statistics, Peking University First Hospital, Beijing, China
| | - Xiaoyan Yan
- Peking University Clinical Research Institute, Beijing, China
| | - Meixia Shang
- Department of Medical Statistics, Peking University First Hospital, Beijing, China
| | - Shufang Wang
- Hefei Yifan Biopharmaceuticals Inc., Economic Development Zone, Hefei, China
| | - Fengyuan Chang
- Hefei Yifan Biopharmaceuticals Inc., Economic Development Zone, Hefei, China
| | - Xiaopei Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - Jun Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - Yuqin Song
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| |
Collapse
|
39
|
Sahgal A, Myrehaug S, Siva S, Masucci L, Foote M, Brundage M, Butler J, Chow E, Fehlings M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Maralani P, Thibault I, Wong R, Hum M, Ding K, Parulekar W. CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases. Int J Radiat Oncol Biol Phys 2020; 108:1397-1398. [DOI: 10.1016/j.ijrobp.2020.09.019] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Song A, Ding K, Laperriere N, Perry J, Mason W, Winch C, O'Callaghan C, Menten J, Brandes A, Phillips C, Fay M, Nishikawa R, Osoba D, Cairncross G, Roa W, Wick W, Shi W. Impact of Lymphopenia on Survival for Elderly Patients with Glioblastoma: A Secondary Analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) Randomized Clinical Trial. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
41
|
Han D, Hooshangnejad H, Chen C, Ding K. A Novel Use of Hydrogel as a Dual-Buffer in Stereotactic Body Proton Therapy for Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
42
|
Hooshangnejad H, Youssefian S, Ding K. Virtual Spacer Implantation Platform Based on Finite Element Method for Simulation and Planning Patient-Specific Spacer Placement. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.723] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Chen H, Meyer J, Narang A, Han-Oh S, Ding K, Wong J, Tsien C, Li H. Delivery Uncertainty Estimation Using Daily Breath-Hold Cone-Beam CTs For Liver Proton Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Han-Oh S, Hill C, Wang K, Ding K, Li H, Chen H, Meyer J, Narang A. Dosimetric Impact of Deep Inspiration Breath Hold Uncertainty on Pancreas Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
45
|
Gillen J, Essel K, Burkett W, Dvorak J, Ding K, Zheng B, Thai T, Moore K. Adiposity and influence on response to immunotherapy. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
46
|
Fang Y, Chen HQ, Zhang X, Zhang H, Xia J, Ding K, Fang ZY. Probiotic administration of lactobacillus rhamnosus GR-1 attenuates atherosclerotic plaque formation in ApoE-/- mice fed with a high-fat diet. Eur Rev Med Pharmacol Sci 2020; 23:3533-3541. [PMID: 31081110 DOI: 10.26355/eurrev_201904_17722] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To investigate the effect of Lactobacillus rhamnosus GR-1 on atherosclerotic progression in apolipoprotein-E knockout (ApoE-/-) mice fed with a high-fat diet and the underlying mechanisms of its action. MATERIALS AND METHODS Eight-week-old ApoE-/- mice were treated with Lactobacillus rhamnosus GR-1 daily for 12 weeks. ApoE-/- mice in the vehicle group and wild type (WT) mice were treated with normal saline. Serum lipid levels, histopathological analysis of the aorta, oxidative and inflammatory indexes and activation of the nuclear factor-kappa B (NF-κB) signaling pathway were examined. RESULTS Compared to ApoE-/- mice in the vehicle group, no changes in body weight or serum lipid levels were found in ApoE-/- mice treated with Lactobacillus rhamnosus GR-1. However, the administration of GR-1 slowed down the development of atherosclerosis and reduced plaque formation. Additionally, GR-1 attenuated the development of oxidative stress and chronic inflammation in a dose-dependent manner in ApoE-/- mice fed a high-fat diet. Furthermore, in ApoE-/- mice treated with GR-1, GR-1 was demonstrated to have a role in inhibiting the translocation of NF-κB p65 from the cytoplasm to the nucleus and suppressing the degradation of IκB-α. CONCLUSIONS We showed that the administration of GR-1 decreased atherosclerotic lesion size in ApoE-/- mice by reducing oxidative stress and inflammation. Additionally, the NF-κB signaling pathway might mediate these effects.
Collapse
Affiliation(s)
- Y Fang
- First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
| | | | | | | | | | | | | |
Collapse
|
47
|
Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Vélot L, Ding K, Caron P, Lacombe L, Lévesque É, Klotz L, Guillemette C. Evaluation of the contribution of extragonadal steroids to androgen receptor activity and to castration resistance development in recurrent prostate cancers after primary therapy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33822-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
48
|
Mcinnes I, Behrens F, Mease PJ, Kavanaugh A, Ritchlin CT, Nash P, Gratacos-Masmitja J, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L. OP0227 SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Secukinumab (SEC), an interleukin-17A inhibitor, has demonstrated improvements on multiple domains of psoriatic arthritis (PsA).1Adalimumab (ADA), a TNF inhibitor, is widely used as a first–line biologic in PsA.Objectives:To report efficacy and safety outcomes from the head-to-head EXCEED trial (NCT02745080) that compares SECvs.ADA as first–line biologic monotherapy through 52-weeks (wks), with a musculoskeletal primary endpoint in pts with active PsA.Methods:Head-to-head, phase-3b, randomised, double-blind trial: biologic naïve active PsA pts were randomised to receive SEC 300mg subcutaneous at baseline, Wk1-4, and then every 4wks (q4w) until Wk48 or ADA 40mg subcutaneous at baseline and then q2w until Wk50. The primary endpoint was superiority of SECvs.ADA on ACR20 response at Wk52. Binary and continuous variables were analysed using logistic-regression model and MMRM, respectively. Safety analysis included patients who received ≥1 dose of study-drug.Results:853 pts were randomised to receive SEC (n=426) or ADA (n=427). Baseline demographics and disease characteristics were comparable between treatment-groups except higher proportion of female pts and pts without enthesitis in the SEC group. ACR20 response at Wk52 for SECvs.ADA were 67·4%vs.61·5%, respectively (p=0·0719) (Figure). Higher clinical responses were observed with SECvs.ADA for a range of musculoskeletal, skin, and higher-hurdle outcomes (Table). A higher retention rate was observed for SEC (85.7%)vs.ADA (76.3%). Safety profiles of SEC and ADA were consistent with previous reports.2,3Conclusion:Results suggest that SEC is at least as efficacious as ADA on musculoskeletal endpoints whilst providing higher responses on skin endpoints, and is associated with a higher retention rate. No new safety signals were reported.References:[1]van der Heijde, et al. Rheumatol. (Oxford).2019; DOI10.1093/rheumatology/kez420.[2]Deodhar A, et al. Arthritis Res Ther. 2019;21:111.[3]Burmester GR, et al. Ann Rheum Dis.2013; 72:517-24.Figure.ACR20 Response through Wk 52Table.Efficacy Outcomes at Wk 52Endpoints, % response unless specified otherwiseSEC 300 mg(N=426)ADA 40 mg(N=427)P-value (unadjusted)*ACR2067·461·50·0719aACR2066·959·50·0239Key SecondarybPASI 9065·443·2<0·0001ACR5049·044·80·2251HAQ-DI mean change from baseline ± SE-0·58 ± 0.03-0·56 ± 0.030·5465cResolution of enthesitis (based on LEI)60·554·20·1498ExploratoryMDA43·037·90·1498VLDA18·116·60·6107DAPSA LDA+Remission61·753·10·0178PASDAS LDA+Remission51·144·10·0557*Unadjusted P-valuesvsADABinary variables were analysed using logistic regression. Pts who discontinued study treatment prematurely or took csDMARDs after week-36 were considered non-responders. Multiple imputation was used for all other missing data. HAQ-DI mean change from baseline was analysed using mixed-effect model repeated measuresaNon-responder imputation was used for pre-specified sensitivity analysisbN=215 in SEC and N=202 in ADA in psoriasis subsetcN=234 in SEC and N=264 in ADA in enthesitis subsetDisclosure of Interests:Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Frank Behrens Grant/research support from: Pfizer, Janssen, Chugai, Celgene, Lilly and Roche, Consultant of: Pfizer, AbbVie, Sanofi, Lilly, Novartis, Genzyme, Boehringer, Janssen, MSD, Celgene, Roche and Chugai, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Arthur Kavanaugh Grant/research support from: Abbott, Amgen, AstraZeneca, BMS, Celgene Corporation, Centocor-Janssen, Pfizer, Roche, UCB – grant/research support, Christopher T. Ritchlin Grant/research support from: UCB Pharma, AbbVie, Amgen, Consultant of: UCB Pharma, Amgen, AbbVie, Lilly, Pfizer, Novartis, Gilead, Janssen, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Jordi Gratacos-Masmitja Grant/research support from: a grant from Pfizzer to study implementation of multidisciplinary units to manage PSA in SPAIN, Consultant of: Pfizzer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly, Speakers bureau: Pfizzer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly, Philippe Goupille Grant/research support from: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Lilly, Janssen, Medac, MSD France, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Consultant of: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Lilly, Janssen, Medac, MSD France, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Speakers bureau: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Lilly, Janssen, Medac, MSD France, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Tatiana Korotaeva Grant/research support from: Pfizer, Consultant of: Abbvie, BIOCAD, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novartis-Sandoz, Pfizer, UCB, Speakers bureau: Abbvie, BIOCAD, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novartis-Sandoz, Pfizer, UCB, Alice B Gottlieb Grant/research support from:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Consultant of:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Speakers bureau:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Ruvie Martin Shareholder of: Novartis, Employee of: Novartis, Kevin Ding Employee of: Novartis, Pascale Pellet Shareholder of: Novartis, Employee of: Novartis, Shephard Mpofu Shareholder of: Novartis, Employee of: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis
Collapse
|
49
|
Gottlieb AB, Behrens F, Nash P, Merola JF, Ding K, Pellet P, Pricop L, Mcinnes I. FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Psoriatic arthritis (PsA) is a heterogeneous disease comprising musculoskeletal and dermatological manifestations, especially plaque psoriasis.1Secukinumab (SEC), an IL-17A inhibitor, provided significantly greater PASI 75/100 responses in a head-to-head trialversus (vs.) etanercept, a TNF inhibitor, in patients (pts) with moderate-to-severe plaque psoriasis.2The objective of the EXCEED study (NCT02745080) was to investigate whether SEC is superior to adalimumab (ADA), a TNF inhibitor, as monotherapy in biologic-naive active PsA pts with active plaque psoriasis (defined as having at least one psoriatic plaque of ≥2 cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis).Objectives:To report the pre-specified skin outcomes from the EXCEED study in the subset of pts with at least 3% body surface area (BSA) affected with psoriasis at baseline.Methods:Head-to-head, phase-3b, randomised, double-blind, active-controlled, multicentre, parallel-group trial: pts were randomised to receive SEC 300 mg subcutaneous at baseline, Week 1-4, followed by dosing every 4 weeks (q4w) until Week 48 or ADA 40 mg subcutaneous at baseline followed by same dosing q2w until Week 50. The primary endpoint was superiority of SECvs.ADA on ACR20 response at Week 52. Pre-specified outcomes included the proportion of pts achieving a combined ACR50 and PASI 100 response, PASI 100 response, and absolute PASI score ≤3. Missing data was handled using multiple imputation.Results:853 pts were randomised to receive SEC (n=426) or ADA (n=427). At baseline, there were 215 and 202 pts having at least 3% BSA affected with psoriasis in the SEC and ADA groups, respectively. A higher proportion of patients achieved simultaneous improvement in ACR50 and PASI 100 response with SECvs.ADA (30·7%vs.19·2%; P=0·0087 [Figure]). Higher efficacy was demonstrated for SECvs.ADA for PASI 100 responses and for the proportion of pts achieving absolute PASI score ≤3 (Table).Conclusion:In this pre-specified analysis, SEC provided higher responses compared to ADA in achievement of simultaneous improvement of joint and skin disease (combined ACR50 and PASI 100 response) and in skin specific endpoints (PASI 100 and PASI score ≤3) at Week 52.References:[1]Coates LC and Helliwell PS.Clinical Med.2017;17:65–70.[2]Langley RG et al.N Engl J Med.2014;371:326–38.Figure.Combined ACR50 and PASI 100 Response through Week 52Table.Skin Specific Outcomes at Week 52Endpoints, data is presented as % responseSEC 300 mg(N = 215)ADA 40 mg(N = 202)P-value (unadjusted)PASI 10046·029·70·0007Absolute PASI score ≤379·265·00·0015P value vs. adalimumab; Unadjusted P values are presentedN, number of patients in psoriasis subsetMultiple imputation was used for handling missing dataADA, adalimumab; BSA, body surface area; PASI, psoriasis area severity index; SEC, secukinumabAcknowledgments:Suchita Dubey (Novartis) provided medical writing support.Disclosure of Interests:Alice B Gottlieb Grant/research support from:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Consultant of:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Speakers bureau:: Research grants, consultation fees, or speaker honoraria for lectures from: Pfizer, AbbVie, BMS, Lilly, MSD, Novartis, Roche, Sanofi, Sandoz, Nordic, Celltrion and UCB., Frank Behrens Grant/research support from: Pfizer, Janssen, Chugai, Celgene, Lilly and Roche, Consultant of: Pfizer, AbbVie, Sanofi, Lilly, Novartis, Genzyme, Boehringer, Janssen, MSD, Celgene, Roche and Chugai, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Joseph F. Merola Consultant of: Merck, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB Pharma, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres and LEO Pharma, Kevin Ding Employee of: Novartis, Pascale Pellet Shareholder of: Novartis, Employee of: Novartis, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB
Collapse
|
50
|
Reshchikov MA, Vorobiov M, Andrieiev O, Ding K, Izyumskaya N, Avrutin V, Usikov A, Helava H, Makarov Y. Determination of the concentration of impurities in GaN from photoluminescence and secondary-ion mass spectrometry. Sci Rep 2020; 10:2223. [PMID: 32041980 PMCID: PMC7010669 DOI: 10.1038/s41598-020-59033-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Accepted: 01/23/2020] [Indexed: 11/09/2022] Open
Abstract
Photoluminescence (PL) was used to estimate the concentration of carbon in GaN grown by hydride vapor phase epitaxy (HVPE). The PL data were compared with profiles of the impurities obtained from secondary ion mass spectrometry (SIMS) measurements. Comparison of PL and SIMS data has revealed that apparently high concentrations of C and O at depths up to 1 µm in SIMS profiles do not represent depth distributions of these species in the GaN matrix but are rather caused by post-growth surface contamination and knocking-in impurity species from the surface. In particular, PL analysis supplemented by reactive ion etching up to the depth of 400 nm indicates that the concentration of carbon in nitrogen sites is below 2-5 × 1015 cm-3 at any depth of GaN samples grown by HVPE. We demonstrate that PL is a very sensitive and reliable tool to determine the concentrations of impurities in the GaN matrix.
Collapse
Affiliation(s)
- M A Reshchikov
- Department of Physics, Virginia Commonwealth University, Richmond, VA, 23220, USA.
| | - M Vorobiov
- Department of Physics, Virginia Commonwealth University, Richmond, VA, 23220, USA
| | - O Andrieiev
- Department of Physics, Virginia Commonwealth University, Richmond, VA, 23220, USA
| | - K Ding
- Department of Electrical Engineering and Computer Science, Virginia Commonwealth University, Richmond, VA, 23220, USA
| | - N Izyumskaya
- Department of Electrical Engineering and Computer Science, Virginia Commonwealth University, Richmond, VA, 23220, USA
| | - V Avrutin
- Department of Electrical Engineering and Computer Science, Virginia Commonwealth University, Richmond, VA, 23220, USA
| | - A Usikov
- Saint-Petersburg National Research University of Information Technologies, Mechanics and Optics, 49 Kronverkskiy Ave., 197101, Saint Petersburg, Russia
| | - H Helava
- Nitride Crystals, Inc. 9702 Gayton Road, Ste. 320, Richmond, VA, 23238, USA
| | - Yu Makarov
- Nitride Crystals, Inc. 9702 Gayton Road, Ste. 320, Richmond, VA, 23238, USA
| |
Collapse
|